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3. ABSTRACT
Background and objective: Oral lichen planus (OLP) is a common immune
disorder of the oral mucosa, which is categorized as an oral potentially malignant
disorder (OPMD) to highlight its potential progression to oral cancer. Oral cancer
commonly affects the mobile tongue as oral tongue squamous cell carcinoma
(OTSCC), which has dismal prognosis. Histamine signals via four G protein-coupled
histamine receptors (H1R-H4R). Classical H1R and H2R medications are ineffective
in treating OLP or OTSCC patients. The discovery of H4R has paved the way for
novel perspectives in histamine research by modulating immune responses. We
therefore hypothesized that H4R is involved in the pathogenesis of OLP and may
contribute to oral carcinogenesis.
Materials and methods: Tissue samples from OLP, oral epithelial dysplasia (OED)
and OTSCC patients, and from healthy control participants were utilized. The in vitro
experiments were performed on normal human oral keratinocytes (HOKs), two
OTSCC-derived cell lines (HSC-3 and SCC-25), normal salivary gland cells, in
addition to supernatants from activated human mast cells (MCs). For in vitro
internalization and functional assays, two specific H4R ligands (agonist HST-10, and
inverse agonist ST-1007) were used. Protein expression of histamine receptors,
transporters and metabolizing enzymes, and other antigens were assessed in tissue
samples and cell lines by immunohistochemistry and immunofluorescence staining.
The expression levels of mRNA were quantified by qRT-PCR and the highly-
sensitive droplet-digital PCR technology. Western blotting assays were performed
to assess apoptotic markers following H4R stimulation, while flow cytometry was
used to study Annexin-V and PI labelling of dead cells. Histamine levels were
analysed using high-performance liquid chromatography.
Results: Briefly,  H4R  is  expressed  in  healthy  oral  epithelial  cells  on  mRNA  and
protein levels, and they were able to fully internalize H4R-ligands in a time-
dependent  manner.  In  contrast,  samples  from  OLP,  OED  and  OTSCC  patients
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exhibited lower H4R level, which was negatively correlated with MC-count and
OTSCC-grade. We also reported that normal HOKs are histamine-producing cells—
fully equipped with histamine synthesizing, transporting and degrading molecules.
Interestingly, OLP samples exhibit high levels of the histamine synthesizing and
transporting molecules, whereas histamine degrading enzyme was strongly
inhibited. HOKs showed a dose-dependent Lipopolysaccharides (LPS)-driven
release of histamine, while high histamine levels inhibited epithelial adhesion
molecules. We next showed that toll-like receptors (TLRs) are essential players in
OLP. TLRs were upregulated in OLP lesions, particularly for TLR4, which is
necessary for LPS signalling. Importantly, LPS and MC-mediators regulated several
oral oncogenes, while H4R-stimulated cells revealed a marked resistance to
apoptosis. Furthermore, LPS and histamine influenced human beta defensin 2 (hBD-
2) expression, which was highly induced in OLP. Unexpectedly, hBD-2 protein was
subsided in OTSCC tissues with a marked downregulation of its transcript in cancer
cells. Histamine synergistically induced TNF- - and IFN- -mediated hBD-2
production in HOKs. Interestingly, targeting H4R seems to regulate TNF - and LPS-
mediated expression of hBD-2.
Conclusions: Briefly, human oral epithelial cells are “non-professional” histamine
producing cells—capable to synthesize, release, and degrade low levels of endogenic
histamine. High levels of histamine may downregulate H4R as well as key integrity
molecules in HOKs and may enhance subsequent bacterial invasion in OLP. In this
regard, our findings suggest a potential role of TLRs in OLP pathogenesis, by
mediating LPS signalling and enhancing further immune response and histamine
production. In addition, our results indicate that histamine/H4R crosstalk signalling
with LPS and MCs could in part be involved in OLP and the potential inflammation-
driven tumorigenesis. This was further supported by the ability of H4R to regulate
cell apoptosis and modulate antibacterial response in HOKs. Further functional and
preclinical studies are therefore warranted.
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4. INTRODUCTION
Oral lichen planus (OLP) is common immune-mediated oral inflammatory disease
that affects about 0.5–2.6% of general population (Kanemitsu 2014; Varghese et al.,
2016). Clinically, OLP may present with various white-and-red morphological
changes that can wax and wane over an extended period of time (Müller 2011). The
most common type of OLP is the reticular form. Other forms of OLP include papular,
plaque-like, atrophic, erosive and bullous types. Typically, OLP is found in middle-
aged or elderly patients (Kanemitsu 2014; Cheng et al., 2016). In fact, one of the
most important concerns regarding OLP lesions is their potential progression to oral
cancer (Kanemitsu 2014). Hence, in 1978, the World Health Organization has
categorized OLP, as well as several other lesions, under the term oral potentially
malignant disorders (OPMDs) to highlight their possible tendency for carcinogenesis
in about 1% of cases (Ismail et al., 2007; Speight 2007; Tovaru et al., 2013).
Oral squamous cell carcinoma (OSCC) is one of the most common malignant
tumours in the world with more than 354,864 newly diagnosed cases in 2018
(GLOBOCAN 2018; Bray et al., 2018; Warnakulasuriya 2009; Garavello et al.,
2007). In fact, the lateral borders of the tongue are considered as the most intraoral
OSCC-prone locations (Moore et al., 2000; Torre et al., 2015). Pooling of various
oral carcinogens in these channels has been suggested as a potential explanation for
such location-dependent higher incidence of OSCC (Johnson and Warnakulasuriya
1993; Moore et al., 2000). In spite of the recent advances in cancer management, oral
tongue squamous cell carcinoma (OTSCC) remains to have a relatively poor
prognosis and low survival rate due to its high potential for swift invasion and occult
metastasis (Sano and Myers, 2007; Brinkman and Wong, 2006).
The transformation of normal epithelium to cancer is a complex multistep
process that consists of intricate interactions among environmental and inflammatory
mediators (Gonda et al., 2009). In this regard, chronic inflammation has been
considered as an important contributor to carcinogenesis (Okada 2014). It is hence
13
sensible that OPMDs, such as OLP and lesions exhibiting oral epithelial dysplasia
(OED), predispose patients to an increased risk of oral cancer (Gillenwater et al.,
2006; Speight 2007; Halonen et al. 2018; Yardimci et al., 2014). Therefore, a better
understanding of the molecular mechanisms involved in such gradual tumorigenic
process  could  pave  the  way  for  developing  more  effective  drugs  for  OTSCC
prevention and treatment. Importantly, oral cavity is easy to examine and risk factors
for oral cancer are known; therefore there is a considerable opportunity to improve
the patient prognosis and survival rate through better diagnostic and therapeutic
approaches of OPMDs and early-stage OTSCC (Gillenwater et al., 2006).
Histamine [2-(4-imidazolyl)-ethylamine] is a pleiotropic biogenic amine
found in most tissues of the body, and it is highly elevated in chronic inflammatory
lesions and autoimmune diseases (Smuda and Bryce 2011). It mediates its
pathophysiological effects via four G-protein-coupled receptors (H1R through H4R),
which are expressed in different cell types (Dy and Schneider, 2004). Histamine is
synthesized in a wide variety of cell types, however, mast cells (MCs) represent the
most relevant source of histamine in the immune system, where it is stored in large
intracellular granules (Riley and West, 1952; Maintz and Novak, 2007; Borriello et
al., 2017). Once exposed to various immunologic stimuli, MCs release histamine in
large amounts into extracellular milieu. These stimuli can be immunologic like
allergens and pathogens, or non-immunologic stimuli, such as neuropeptides,
lipoproteins, adenosine, superoxidases and physical traumas (Vlieg-Boerstra et al.,
2005; Maintz and Novak, 2007; Smuda and Bryce 2011).
Of note, most cancer cell lines and tumour models exhibit the histamine-
synthesizing enzyme, L-histidine decarboxylase (HDC), and associate with high
levels of endogenous histamine, which showed the potential to regulate tumour
growth (Bartholeyns and Fozard, 1985; Garcia-Caballero et al., 1994; Medina and
Rivera, 2010). In spite of the successful history of histamine-derived medications in
treating many diseases, clinical trials proved, however, ineffectiveness of targeting
14
classical  H1R  and  H2R  to  treat  OPMDs  or  OTSCC  patients  (Day  et  al.,  2003;
Gillenwater  et  al.,  2006;  Lodi  et  al.,  2012;  Wolff  et  al.,  2012).  The  discovery  of
histamine H4 receptor (H4R) and its varying expression within a wide range of
tissues, including tumours, have paved the way for novel perspectives in histamine
research (Zampeli and Tiligada, 2009). In fact, H4R exhibits about 10,000-fold more
affinity for histamine compared with other conventional histamine receptors, such as
H1R (Thurmond et al., 2008). As expected, H4R antagonists showed marked clinical
effects in atopic dermatitis (AD) patients as well as in preclinical models of asthma
(Ohsawa et al., 2014; Thurmond, 2015). Moreover, targeting H4R suppresses the
proliferation and invasion of esophageal squamous cell carcinoma via different
signalling pathways (He et al., 2018). Furthermore, H4R modulated the proliferation
of breast, lung, pancreatic, ovarian and colon cancer cell lines (Massari et al., 2018).
Overall, the identification of H4R, along with the enormous pharmaceutical
success of drugs targeting the H1R and H2R, has generated immediate interest in
this novel receptor, which has shortly paved the way for new era of studies on the
immunomodulatory histamine/H4R-mediated effects (Hough, 2001; Thurmond,
2015). Consequently, efforts are still ongoing to understand the function of this new
receptor and to determine if it can represent a viable drug target. The aim of this
study was, therefore, to explore the role of H4R in OLP, as a model of OPMDs, and
its potential contribution to development of OTSCC.
15
5. LITERATURE REVIEW
5.1. Human oral mucosa
The oral cavity is separated from the outer environment by a mucous membrane
barrier that is called oral mucosa. Oral mucosa is categorized in general into
keratinized and non-keratinized mucosa. The keratinized mucosa helps to resist hard
mechanical forces induced by mastication, and it involves the mucosae of hard palate
and marginal gingiva. These tissues undergo terminal differentiation resulting in
dead (cornified) squames lacking nuclei or vital organelles and containing keratin,
and thus impart protection to such areas (Presland and Jurevic, 2002). Non-
keratinized mucosa helps to facilitate speech and swallowing, and it is primarily
found in the soft palate, floor of the mouth, buccal mucosa, alveolar mucosa, and
lips. In spite of the histology and thickness variations, each type of oral mucosa
imparts protection against mechanical damage and preserves the underlying
structures according to the functional demand of its location (Dale et al., 1990; Squier
and Kremer, 2001; Presland and Jurevic, 2002).
Oral mucosa is composed of two distinct parts: 1) the stratified squamous cell
epithelium layers; and 2) the lamina propria (Figure  1). The oral epithelium is
composed of stratified squamous cells and separated from the lamina propria by the
basement membrane (BM). The oral epithelium consists of several layers depending
on the type of mucosa whether keratinized or non-keratinized. In keratinized mucosa,
the  epithelium  consists  of  four  layers:  stratum  basale  or  basal  layer,  stratum
spinosum or prickle layer, stratum granulosum or granular layer, and stratum
corneum or the keratinized layer. In non-keratinized mucosa, it consists of basal cell
layer, prickle cell layer, intermediate and superficial cell layers. The basal cell layer
is the dividing layer—it separates the epithelium from the underlying lamina propria
and maintains the epithelial cell flow.
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In addition to keratinocytes, oral epithelium contains also some different cell
types, including melanocytes, Langerhans’ cells, and Merkel cells (Squier and Hill,
1989; Squier and Kremer, 2001; Moharamzadeh et al., 2012). The lamina propria
consists of loose connective tissue that supplies the oral mucosa with blood vessels,
nutrients and nerves, and separates the oral mucosa from the underlying tissue, bone,
fat or muscles. Many cell types are found in the lamina propria, including endothelial
cells, fibroblasts, MCs, macrophages, as well as lymphocytes and plasma cells.
Epithelial adhesion to the extracellular matrix is vital to maintain tissue
integrity and for the maintenance of systemic and oral health. Pathogens will first
encounter the host at epithelial-mucosal interface, and therefore it is not surprising
that oral epithelium takes a central part in defending underlying tissues from
pathogenic onslaught. Such protective mechanisms comprise development of a
tightly sealed physical barrier, releasing of direct antibacterial peptides, and
organizing both innate and adaptive immune responses (Groeger and Meyle, 2015).
Furthermore, following tissue physical injury or wounding, epithelial cells offer
immediate protective responses by initiating the epithelial cover and restore the
deranged barrier against pathogenic infections (Presland and Jurevic, 2002).
In oral epithelium, cytokeratins are the most abundant proteins and main
component of keratinized epithelium, which are attached with desmosomes to form
extensive cadherin-mediated cytoskeletal architectures (Presland and Jurevic, 2002).
Desmosomes play crucial role in maintaining the epithelial intercellular adhesion
while hemidesmosomes promoting the adhesion of epithelial cells to the underlying
BM (Borradori and Sonnenberg, 1999). Additionally, epithelial cells tightly connect
with  each  other  by  gap  and  tight  junctions,  which  promote  cell  signalling  and
regulate selective movement of solutes across the epithelium, respectively (Bazzoni
and Dejana, 2002).
17
Figure 1. Histological features of human oral mucosa.
5.2. Oral lichen planus: definition and incidence
Oral  lichen  planus  (OLP),  which  was  first  described  by  Dr.  Wilson  in  1869,  is  a
common chronic inflammatory disease that affects oral mucosa with yet unknown
etiology and unclear pathogenesis (Cheng et al., 2016). While cutaneous lesions of
lichen planus, in most of cases, are self-limiting, OLP lesions are chronic, less likely
to undergo spontaneous remission, and exhibit high potential to develop significant
complications (Edwards and Kelsch, 2002; Eisen 2002). In the same context, the
World Health Organization (WHO) has regarded OLP as a potentially malignant
lesion that is associated with an increased risk of oral cancer (Kramer et al., 1978;
van der Waal 2009; El-Naggar et al., 2017). Approximately 60% of cutaneous LP
patients exhibit oral manifestations; while only 15% of OLP patients develop
cutaneous lesions (Crincoli et al., 2011; De Rossi and Ciarrocca, 2014; Cheng et al.,
2016).
Epidemiologically, OLP is one of the most common non-infectious oral
mucosal diseases in adults affecting between 0.5 to 2.6% of population, although the
percentage was up to 5% in some reports (Thorn et al. 1988; Sugerman et al. 2000;
Eisen 2002; Gorouhi et al., 2014). OLP has a higher incidence (over than 60% of
18
cases) in women than in men (Eisen 2002, Xue et al., 2006, Bermejo-Fenoll et al.
2010). The disease may arise at any age but it is most commonly diagnosed in
persons  between 30  to  80  years  of  age  (Thorn  et  al.  1988;  Eisen  2002;  Bermejo-
Fenoll et al. 2010; Regezi et al. 2017). However, OLP incidence in younger patients
and children have also been reported (Kanwar and De, 2010).
5.3. Clinical features
OLP patients commonly experience lesions with bouts of exacerbations and
remission, and varying degrees of intensity (Wang and van der Waal, 2015). The
active lesions have distinctive clinical features and characteristic bilateral
distribution commonly on buccal, tongue and gingival mucosa (Eisen et al., 2005;
Carbone et al., 2009).
The most common
area of OLP lesions is
in the buccal mucosa,
and the second most




et al., 2011). It is,
however, less common
to find OLP lesions on
other mouth regions
like palate, floor of the
mouth or lip vermilion
(Thorn et al. 1988; Edwards and Kelsch 2002; Eisen 2002). There are six clinical
variants for OLP lesions, namely: reticular, atrophic, ulcerative, papular, bullous,
and plaque-type lesions (Andreasen 1968; Thorn et al. 1988; Alrashdan et al., 2016;
Figure 2. Common clinical forms of OLP: a) reticular; b)
combination of reticular, atrophic and ulcerative; c) atrophic;
d) plaque-like form. Figures were kindly provided by Dr.
Siponen M.
19
Figure 2). It is not uncommon for the same patient to exhibit several variants of OLP
lesions occurring simultaneously (Figure 2b; Edwards and Kelsch, 2002; Alrashdan
et al., 2016).
The most common pattern of OLP is the reticular form, which is often
asymptomatic and exhibits multiple interweaved papules with lacy and elevated
whitish  lesions  known  as  Wickham’s  striae  (Eisen  2002;  Eisen  et  al.,  2005;
Alrashdan et al., 2016). Atrophic and erosive variants of OLP are also common, and
they  are  often  associated  with  considerable  pain  and  discomfort  (Eisen  2002;
Gorouhi et al., 2014). Erosive OLP lesions may involve local erythematous patches,
induced by inflammatory responses, and ulcerative lesions, enclosed by thinly
radiating keratotic striae (Gorouhi et al., 2014; Edwards and Kelsch, 2002; Eisen
2002). When the atrophic/erosive forms of OLP affect the attached gingivae, the
condition may be termed desquamative gingivitis (Rogers et al., 1982; Edwards and
Kelsch 2002). The papular and bullous lesions appear as tiny whitish papules or soft
mucous extensions. These lesions are less commonly encountered forms of OLP and
usually seen in the buccal mucosa and lateral border of tongue (Thorn et al. 1988).
Plaque-like OLP lesions are more frequent in smokers and they are usually affecting
buccal mucosa and tongue (Thorn et al. 1988).
5.4. Microscopic features
The classical histopathological triad of OLP includes: 1) dense and confluent band-
like inflammatory cell infiltrate (consisting mainly of T-cells) in the lamina propria;
2) degenerated BM; and 3) apoptotic basal keratinocytes (Figure 3; Kramer et al.,
1978; Epstein et al., 2003; Rad et al., 2009). The degenerated basal keratinocytes
(i.e. apoptotic cells and cells with hydropic changes) tend to form structures in the
lower epidermis known as “Civatte bodies” or eosinophilic colloid bodies, which
contain DNA fragments and immunoglobulins from the apoptotic basal cells
(Burgdorf and Plewig, 2014). Moreover, the basal cell layer manifests signs of
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degeneration such as elongated cytoplasmic processes, and widening in intercellular
spaces (Paul and Shetty, 2013). Furthermore, degeneration of BM is usually
observed as breaks, irregular branches and patch-like disruptions (Jungell P et al.,
1987). It is also common to find inflammatory cells within the epithelial layers in
OLP tissues (Bloor et al., 1999; Neppelberg et al., 2001; Sugerman et al. 2002;
Fernández-González et al., 2011).
Other less-specific histopathological features of OLP include hyperkeratosis
(ortho- or parakeratosis), shortened/pointed (saw-teeth) rete pegs that can be also
lost, acanthosis, epithelial atrophy, and alteration of the epithelial anchoring
elements (Sugerman et al. 2002; Fernández-González et al., 2011; Haapalainen et
al.,  1995).  As  a  result  of  epithelial  degeneration  and  apoptotic  basal  cells,  the
epithelial barrier in OLP lesions, in general, is thinner compared with normal oral
mucosa, and hence it offers less protection against physical and chemical trauma
(Karatsaidis et al., 2003).
The inflammatory cell infiltrate consists predominantly of activated cytotoxic
(CD8+) and helper (CD4+) T-lymphocytes. Additionally, there are increased counts
of local “degranulated” MCs, dendritic cells (Langerhans cells), natural killer cells,
and macrophages (Iijima et al., 2003; Santoro et al., 2005; Salem et al., 2015; Choi
et al., 2016). When making a diagnosis of a seemingly OLP lesion, it is important to
assess both clinical and histopathological features to rule out any other similar
conditions and malignant diseases (Cheng et al., 2016).
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Figure 3. Main histopathological features of oral lichen planus.
5.5. Etiology
Although OLP is considered one of the most extensively studied oral lesion for over
than a century, the actual etiology of the disease remains unknown. However, some
predisposing factors have been attributed to its pathogenesis, including genetic
factors, mechanical trauma, autoimmunity, metal allergy and smoking (Gorouhi et
al., 2014; Cheng et al., 2016).
5.6. Genetic factors
Some recent reports support the close association between genetic predisposition and
OLP pathogenesis. For instance, Wu et al. examined the association between
mitochondrial DNA haplogroups and susceptibility to OLP in 242 Chinese patients,
and they found that a certain haplogroup (i.e. B4) had a significantly higher incidence
in controls than in OLP patients, implying this haplogroup may play a protective role
in OLP susceptibility (Wu et al., 2014).
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OLP lesions  were  also  determined  in  a  recent  twin  study  to  determine  the
genetic burden of the disease (Wei et al., 2018). In the same context, a former report
of family-related OLP patients indicated that there may be some genetic
predisposition toward OLP (Bermejo-Fenoll and López-Jornet, 2006). Furthermore,
several studies highlighted the potential role of genetic background in OLP
pathogenesis, including gene polymorphisms of TNF-  and IL-10 (Xavier et al.,
2007; Bai et al., 2009), IFN-  (Kimkong et al., 2012; Al-Mohaya et al., 2016).
However, a recent meta-analysis study failed to prove any statistical associations
between the polymorphisms of IL-6 and IL-10 and susceptibility to OLP, which
necessitates the need to more well-designed studies with larger sample sizes (Shi et
al., 2017).
5.7. Systemic diseases
Many research studies that have been carried out over the last few decades have shed
light on the relationship between OLP and several systemic diseases. Such potential
causative relationship is summarised in Table 1.
5.8. Differential diagnosis
There are several oral mucosal lesions that exhibit a multifocal bilateral presentation
as in OLP, and hence they should be considered when making a clinical differential
diagnosis (Dissemond 2004; Lopes et al., 2015; Regezi et al., 2017). Such lesions
may include oral lichenoid lesions (OLLs), proliferative verrucous leukoplakia
(PVL), lupus erythematosus, graft-versus-host disease, and candidiasis. Therefore,
in addition to the clinical and histopathological features (i.e. clinicopathologic
correlation), precise diagnosis should also take into consideration the course history
of  the  disease  (Alrashdan  et  al.,  2016;  Regezi  et  al.,  2017).  Overall,  a  definitive
diagnosis of OLP is highly crucial due to the implications for therapeutic
management (Müller 2011; Cheng et al., 2016; Müller 2017).
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Table 1. The possible association between OLP and certain systemic diseases
Disease Association aspects References
Viral  HCV seropositivity was increased in OLP
patients compared with controls.
 HCV-specific  T-cells  were  found  in  the  oral
mucosa of OLP/HCV patients.
 EBV genome and specific serum antibodies was
found in OLP patients.
 Some literatures indicated a higher incidence of
HPV, HSV-1, HSV-6 and CMV in OLP patients.
Lodi et al., 2010;
Pilli et al., 2002;
Pedersen 1996;
Shariati et al.,
2018; Ma et al.,
2016; Mattila et
al., 2012; Yildirim
et al., 2011; Ding
et al., 2017.
Autoimmune  Autoimmunity has been suggested to play a key
role in OLP pathogenesis.
 OLP patients have higher levels of circulating
antibodies (e.g. antinuclear, autoantibodies).
 Certain autoimmune diseases have been linked
with OLP, such as Sjögren's syndrome,
systemic lupus erythematosus, Hashimoto's







2013; Lo et al.,
2013; Sardana et
al., 2002; Li et al.,
2017.
Psychological  Some observational studies and case reports
showed an association between anxiety, stress
and OLP incidence. However, there is no strong
evidence to support such observations so far.
 Discomfort from OLP lesions or the associated
anxiety about its malignant potential could lead
to a deteriorated psychological state, and thus






Pippi et al., 2016;
HCV: Hepatitis C virus; EBV: Epstein–Barr virus; HPV: Human papillomavirus; HSV-1:
Herpes simplex virus 1; HSV-6: Human herpesvirus 6; CMV: Cytomegalovirus.
5.9. Management
Currently, there is no specific treatment for OLP, and thus management is
primarily aimed to relieve the patient symptoms (Carbone et al., 2003; Eisen et al.
2005; Scully and Carrozzo 2008; Hodgson and Chaudhry, 2010; Lodi et al., 2012;
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Regezi et al., 2017). Moreover, due to the fluctuation in severity and activity during
the  disease  course,  finding  a  single  and  definitive  treatment  for  OLP  remains
challenging (Thongprasom and Dhanuthai, 2008; Gupta et al., 2017). Nevertheless,
some anti-inflammatory and immunosuppressive medications can provide
satisfactory control of the lesion. Topical corticosteroids, such as clobetasol
propionate, fluocinonide, triamcinolone acetonide, and betamethasone sodium
phosphate are commonly considered as the first-line treatment for OLP (Gupta et al.,
2017). However, the long-term use of topical steroids has been associated with
increased incidence of oral candidiasis (Gonzalez-Moles, 2010). Systemic steroids,
such as cyclosporine, tacrolimus, or prednisolone are indicated in severe OLP lesions
and in patients unresponsive to topical steroids (Gupta et al., 2017). Intralesional
injections of corticosteroids, such as dexamethasone, have also been indicated for
extensive lesions, but they are not consistently effective, and may cause localized
side-effects such as mucosal atrophy and pain (Thongprasom and Dhanuthai, 2008).
Overall,  topical  steroids,  such  as  ointments,  pastes,  gels,  or  mouthwashes,  are
generally recommended over other modes of treatment. In Finland, the available
topical corticosteroids include: 1) mid-potent class such as 0.1% triamcinolone
acetonide, beclomethasone dipropionate or beclomethasone dipropionate
monohydrate, and fluticasonepropionate; 2) potent class such as 0.1%
betamethasone 17-valerate; 3) highly potent preparations such as 0.05%
clobetasolpropionate (Siponen 2017).  Methylprednisolone is available for
intralesional injections, while prednisolone is aimed for systemic treatment of OLP
(Siponen 2017).
Immunosuppressants, including calcineurin inhibitors (e.g. cyclosporine,
tacrolimus, and pimecrolimus) have also been recommended for OLP management
due to their anti-inflammatory effects (McCaughey et al, 2011). Although topical
cyclosporine has been popular choice for treating OLP, Harpenau et al. concluded
that it is not superior to steroids due to its frequent relapse rates, burning sensation
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and higher cost (Harpenau et al, 1995; Gupta et al., 2017). The synthetic derivatives
of vitamin A, retinoids, have been suggested as an effective therapeutic
alternative/adjuvant to corticosteroids (Gupta et al., 2017). In this context,
mouthwashes containing a combination of vitamin and triamcinolone produced more
favourable effects in OLP patients compared to use of steroid alone (Dalirsani et al,
2010).
Laser phototherapy (LPT) has been employed for the management of OLP
lesions.  By using diode- or CO2-laser,  the diseased epithelial  layers together with
the underlying inflammatory component are destroyed via protein denaturation
(Derikvand et al., 2017; Gupta et al., 2017). Dillenburg et al. concluded that LPT
was more effective than topical (0.05%) clobetasol for the treatment of atrophic and
erosive OLP; however, LPT treatment was inferior to other topical steroids such as
dexamethasone and triamcinolone (Dillenburg et al, 2014; Gupta et al., 2017). Based
on these reports, LPT can be used as an adjunct therapy with topical steroids in
refractory cases.
It  is  also important in the management course of OLP patients to maintain
excellent oral hygiene, eliminate any local irritating factors, removing calculi, and
treating any concurring periodontal lesions (Regezi et al., 2017).
5.10. Prognosis and cancer progression
The potential malignant transformation of OLP into squamous cell carcinoma (SCC)
has been an unresolved controversial issue for many decades. It has been reported in
a recent cohort study of 13,100 Finnish female patients that OLP diagnosis is
significantly correlated with an increased risk of cancer of lip, tongue, and oral cavity
(Halonen et al., 2018). However, the rate of malignant transformation in OLP lesions
varies considerably between different reports. In this context, Landini et al. found
that such reported transformation rates generally fall between 0% and 10% among
an accumulating 24097 cases of OLP regardless of the follow up time and diagnostic
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criteria (Landini et al., 2014). Nevertheless, a general estimate of the overall
malignant transformation rate in OLP was estimated as 1.09-2% (Fitzpatrick et al.,
2014; Aghbari et al., 2017; Giuliani et al., 2018). Therefore, it was concluded by
WHO experts that OLP is a potentially precancerous lesion that exhibit an increased
risk of cancer, and hence it was later categorized as a potentially malignant disorder
(van der Waal 2009; Mortazavi et al., 2014).
5.11. Oral potentially malignant disorders
The older term “oral premalignant lesion” is not currently advocated as it implies
that a lesion will inevitably progress to cancer, and hence the alternative term “oral
potentially malignant disorders” or (OPMDs) has been adopted and has become
widely used (Warnakulasuriya et al., 2007; Reibel et al., 2017; Speight et al., 2018).
Such new term, OPMDs, suggests that a progression of the lesion to cancer is only a
potential risk (i.e. more statistically probable).
The category of OPMDs comprises numerous disorders with an elevated risk
of being transformed to SCC including, inter alia, leukoplakia, proliferative, PVL,
erythroplakia, OLP/OLLs, lupus erythematosus, actinic cheilitis, and oral
submucous fibrosis (Mortazavi et al., 2014; Speight et al., 2018). Several factors may
influence the progression of OPMDs to malignant lesions, such as the anatomical
site of the lesions, its clinical pattern, and presence of OED (Speight et al., 2018). In
fact, several OPMDs can share both clinical and histological resemblance and thus
both biopsy and microscopic analysis are necessary to minimize misdiagnosis, and
provide better specific management. In this regard, the initial clinical presentation of
PVL, which has a high tendency to recur after treatment, has close similarities to
OLP, particularly in early stages, such as the presence of multifocal white lesions
and dominance in adult female patients (Lopes et al., 2015). Therefore, it has recently
been suggested that many malignantly transformed cases may represent an under-
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recognized spectrum of PVL, which is characterized by a lichenoid pattern, and
hence could lead to misdiagnosis (Fernandes et al., 2017)
The distribution of OPMDs in oral  cavity can reflect  existing habitual risk
factors, such as betel quid chewing and reverse smoking prevalent in parts of India,
Philippines, and South America. Accordingly, buccal mucosa is the most commonly
affected site in betel quid and Khat (or Catha edulis) chewers (Kassie et al., 2001;
El-Zaemey et al., 2015). On the other hand, OPMDs in palate, for example, is most
the commonly affected site in reverse and pipe smokers (Naveen-Kumar et al., 2016;
Speight et al., 2018). It was reported in a retrospective analysis of OPMDs that 40%
of dysplastic or malignant lesions develop in tongue and floor of mouth (Dos et al.,
2013). Furthermore, Jaber et al. found that most dysplastic lesions that associated
with oral carcinogenesis were found in the lateral and ventral borders of tongue, and
the floor of mouth (Jaber et al., 2003). Buccal mucosa also is considered as a
common site to develop some OPMDs such as leukoplakia, however, it was reported
that buccal leukoplakia is associated with less tendency to develop oral cancer
(Warnakulasuriya and Ariyawardana, 2016). Overall, the most common sites of
malignant transformation of OPMDs were observed in tongue, floor of mouth, palate
and buccal mucosa (Speight et al., 2018; Regezi et al. 2017).
The clinical appearance of OPMDs varies considerably, which may
occasionally render their diagnosis complex or confusing (Speight et al., 2018).
Nevertheless, there is a general agreement in the literature that nonhomogeneous oral
lesions  pose  a  higher  risk  of  malignant  transformation  as  compared  with
homogeneous lesions (van der Waal 2009; Napier and Speight, 2008;
Warnakulasuriya et al., 2008; Speight et al., 2018). Additionally, some other patterns
of OPMDs, such as erosive, ulcerative, and atrophic forms were also reported to
correlate with an increased incidence of OSCC, such as in OLP lesions (Ismail et al.,
2007; Tovaru et al., 2013; Fitzpatrick et al., 2014).
28
5.12. Oral tongue squamous cell carcinoma
Oral tongue (AKA mobile tongue) squamous cell carcinoma (OTSCC) is a subtype
of oral cavity cancer, which is regarded as one of the most common malignancies in
head and neck region, with an increased incidence in recent years (Moore et al., 2000;
Marur and Forastiere, 2016; Ferlay et al., 2015; Siegel et al., 2017). In spite of the
noticeable advances in cancer therapy, OTSCC prognosis and survival rate remain
among the poorest of oral malignancies, due to the relatively swift metastasis to
regional lymph nodes and high cancer-related mortality (Sano and Myers, 2004;
Brinkman and Wong, 2006).
Risk factors for OTSCC development are numerous and their combination
may enhance OTSCC development in susceptible individuals. Various forms of
tobacco, betel quid and Khat chewing, excessive alcohol consumption, and existence
of  OPMDs  are  regarded  among  the  most  prominent  risk  factors  for  OTSCC
(Agnihotri and Gaur, 2014; Scully 2011; Casparis et al., 2015). In this regard, early
diagnosis of OPMDs and malignant lesions of tongue is of a prime importance, as it
corresponds to increased 5-year survival rates and reduced comorbidity, compared
with  the  advanced  stages  of  OTSCC  (Sciubba  2001).  Importantly,  there  is  a
significant association between the delay in diagnosis and increased comorbidity rate
(Teppo and Alho 2009). Despite the fact that oral cavity is easily accessible for
clinical evaluation, yet many OTSCC cases are diagnosed at advanced stages (van
der Waal et al., 2011).
Histopathologically,  OTSCC  is  classified  by  WHO  according  to  its
resemblance to the normal tissue (Thompson 2006), into well differentiated (few
mitotic changes, higher resemblance to normal findings), moderately-differentiated
(less keratinized cancer cells, more atypical mitotic changes and nuclear
pleomorphism), and poorly-differentiated cancer cells (very few or no keratinized
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cells, more frequent atypical mitotic changes, with higher degree of nuclear
pleomorphism).
Clinical staging (i.e. tumor–node–metastasis or cTNM system) of OSCC has
long been used as the main reference for risk evaluation and treatment planning
(Akhter et al., 2011). It is based on assessing tumour diameter (T), lymph node status
(N), and distant metastases (M) (Brierley et al., 2016; Amin et al., 2017). In spite of
its popularity in clinical setting, cTNM staging system has been criticized for not
encompassing the biological behaviour of tumour cells, which remains crucial in
deciding the future outcomes of cancers (Anneroth et al., 1987; Bryne et al., 1992;
Akhter  et  al.,  2011).  Furthermore,  the  prognostic  value  of  cTNM  staging  system,
particularly in early stages of OTSCC, has been questionable (Yanamoto et al. 2013).
Hence, the introduction of new prognostic parameters that taking into account the
biological activity of tumour cells is vital for more precise therapeutic strategies.
Surgical resection and radiation are the mainstay treatment for early-stage
OTSCC patients, while elective neck dissection without or with radiotherapy,
chemotherapy, or both, could be indicated for the advanced cases (Ord and
Blanchaert 2001; Langendijk et al., 2010). In spite of the radical changes in oral
cancer management in the recent decades, it should be taken into consideration that
advanced OTSCC patients are more prone to develop distant metastases and second
primary cancers (Ord and Blanchaert 2001). This may explain the fact that OTSCC
prognosis has not significantly improved, and the 5-year overall survival rate remains
relatively low (Rusthoven et al., 2008; Jadhav and Gupta 2013). Therefore, it is
important to enhance the early diagnosis and follow-up of the OPMDs. Additionally,
investigating various signalling pathways that perpetuate the chronic inflammation
in such OPMDs could improve the diagnostic and preventive strategies, which may
translate to better clinical outcomes in most patients (Sciubba 2001; Ord and
Blanchaert 2001; Bhatia and Burtness 2017).
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5.13. Inflammation and carcinogenesis
The causal relationship between the chronic inflammation and carcinogenesis is not
a new concept but dates back to 1863, when the pathologist Rudolf Virchow reported
that cancer was developed at sites of chronic inflammation and dominated by
“lymphoreticular infiltrate” (Balkwill and Mantovani 2001). Indeed, the recent
extensive research in this field has supported Virchow's hypothesis, and the causal
relationship between chronic inflammation, immune response and carcinogenesis is
now more widely accepted (Balkwill and Mantovani 2001; Coussens and Werb
2001). However, a considerable part of the intricate molecular and cellular signalling
that mediate such relationship remain unresolved (Coussens and Werb 2001).
Several mechanisms were suggested as potential contributors to the
inflammation-mediated tumorigenesis, including the ability of many inflammatory
mediators (e.g. Mediators of nuclear factor- B (NF- B) activation, growth factors
and matrix-proteases) to induce the survival and proliferation rate of affected cells
(Karin and Greten 2005; Grivennikov and Karin 2010). Additionally, in vivo studies
of inflammation-mediated cancer showed that activation of NF- B pathway can
inhibit cancer cell apoptosis by inducing crucial anti-apoptotic genes, such as B cell
lymphoma-extra-large (Bcl-XL) and others (Greten et al., 2004). Moreover, tumour-
associated inflammatory response can downregulate the anti-tumorigenic immune
response and enhance the pro-tumorigenic and angiogenic effector functions in
immune cells, as reported in tumour-associated macrophages (TAMs) and MCs (Sica
et al., 2008; Grivennikov et al., 2010; Varricchi et al., 2017). Activation  of  PI3k
pathway, as reported in OLP, and its downstream events has been also suggested to
play a role in the inflammation-mediated carcinogenesis and subsequent cell
proliferation, motility and invasion (Giacomelli and Covani, 2010; Sonis et al.,
2016).
31
The malignant transformation of normal epithelium to OTSCC is a multistep
progressive process that consists of dynamic and complex interactions between
various environmental and inflammatory mediators (Gonda et al., 2009; Whitmore
and Lamont, 2014; Sun et al., 2016; Ryan and Faupel-Badger, 2016). As discussed,
persistent inflammatory mediators have the potential to facilitate cancer
development through enhancing immune cell infiltration and remodelling of stromal
tissue that seem compatible with oral carcinogenesis (Hanahan and Coussens 2012).
It is therefore sensible that OPMDs, such as OLP, can increase the risks to develop
OTSCC (Yardimci et al., 2014; Casparis et al., 2015; Halonen et al. 2018). Mediators
associated with OPMDs, such as inflammatory cytokines and reactive oxygen
species, can facilitate epigenetic alterations in such lesions and downregulate tumour
suppressor genes (Grivennikov and Karin, 2010). Therefore, a better understanding
of the molecular mechanisms associated with such tumorigenic process will pave the
way for identifying novel and more viable drug targets for OTSCC.
Importantly, tumour microenvironment (TME), such as in OTSCC, is highly
miscellaneous and contains diverse immune cells (including TAMs, lymphocytes,
MCs, etc.) that communicate with tumour cells and shape cancer behaviour (de
Visser et al., 2006). In this regard, it was reported that higher numbers of TAMs in
TME  is  proportionally  correlated  with  treatment  shortcomings  and  can  promote
cancer angiogenesis, invasion, and metastasis (Condeelis and Pollard, 2006;
Murdoch  et  al.,  2008).  Furthermore,  T  lymphocytes  can  have  dual  effects  by
inducing either antitumorigenic or protumorigenic effects, depending on their
effector functions (Kohrt et al., 2005; Grivennikov et al., 2010). For instance,
increased T cell numbers, specifically high CD4+/CD8+ ratios was suggested as
indicator of poor prognosis in breast cancer (Kohrt et al., 2005).
MCs have long been suspected as potential players in cancer pathogenesis.
Recently, these cells were also revealed as potent and versatile effector components
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of TME, where they play far more complex roles than their role in allergy, and thus
representing promising therapeutic targets in cancer (Maciel et al., 2015; Aponte-
López et al., 2018).
5.14. The role of MCs in cancer
MCs can exert both tumor-suppressive and -promoting effects mediated by their
potent, and versatile, granular constituents (Maciel et al., 2015; Varricchi et al., 2017;
Ribatti et al., 2018). Almahmoudi et al. showed in a recent study that MC-derived
IL-17F correlates with better disease-specific survival in OTSCC patients
(Almahmoudi et al., 2018). Likewise, the abundance of stromal MCs in invasive
breast cancer patients was correlated with a favourable prognosis (Dabiri et al.,
2004). In another study, colorectal cancer patients with a low MC count had
significantly deeper depth of invasion and lower rates of metastasis compared with
patients with higher MC count (Tan et al., 2005).
On contrary, it has been documented that MCs are able to induce
angiogenesis in cancer models, where MC-deficient mice exhibited decreased
angiogenesis and metastatic capacities during tumour induction (Ribatti et al., 2001).
This can be explained by the ability of MCs to synthesize and release pro-angiogenic
mediators (e.g. VEGF and IL-8) and proteases (e.g. Matrix metallopeptidase 9,
chymase, tryptase) that can degrade extracellular matrix and potentiate invasion
(Ribatti et al., 2018). Malfettone et al. reported that higher density of tryptase+ MCs
at invasive front of human colon adenocarcinomas was associated with cancer cell
motility  and  dismal  prognostic  outcomes  (Malfettone  et  al.,  2013).  Furthermore,
elevated levels of MCs within TME has been correlated with poor prognosis,
enhanced metastasis, and reduced overall survival in oropharyngeal carcinoma,
melanoma, and prostate cancer (Elpek et al., 2001; Ribatti et al., 2003; Nonomura et
al., 2007).
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Beside  angiogenesis  and  matrix  degradation,  the  contribution  of  MCs  to
carcinogenesis can also include protumorigenic immunoregulation (Kalesnikoff and
Galli 2011; Ribatti et al., 2018). Supporting this role, Gounaris et al. showed that
MCs are essential components for the development of the premalignant adenomatous
colon polyps, and they further demonstrated that MCs can promote tumour
development by inducing immunosuppressive and anti-inflammatory phenotypic
changes in tumour-associated regulatory T cells (Gounaris et al., 2007; Gounaris et
al., 2009). In addition, MCs produce IL-13, which plays a crucial role in TME by
activating TAMs and myeloid-derived suppressor cells (McLeod et al., 2015; Suzuki
et al., 2015). Histamine, the most known MC mediators, has also been linked to the
MC-mediated immunosuppression and was thereby able to increase the risk for
cancer development in animal models (Hart et al., 2001).
In fact, histamine can induce tumour proliferation and progression via
signalling with certain receptor subtypes, while in contrast, targeting histamine with
specific inhibitors has yielded promising antitumorigenic effects (Medina and Rivera
2010; Fernández-Nogueira et al., 2018). Indeed, this places histamine, as one of the
most exploited substances in medicine, in promising therapeutic approaches for
OPMDs and cancer (Martinel Lamas DJ et al., 2013).
5.15. Histamine synthesis, release, and degradation
Histamine [2-(4-imidazolyl)-ethylamine] is a short-acting yet potent endogenous
amine. It derives its name from the Greek word (histos, meaning tissue), which
implies its wide distribution throughout body tissues and involvement in many
physiological and pathological conditions (Smolinska et al., 2014). Histamine is
synthesized only by HDC enzyme, which converts the amino acid L-histidine to
histamine (Maintz and Novak, 2007). HDC is widely expressed in different cell types
and tissues such as central nervous system (CNS), neurons, gastric mucosal tissue,
MCs, basophils, and enterochromaffin-like cells (Thangam et al., 2018; Walter and
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Stark, 2012). There are two isoforms of HDC: 1) low activity full-length 74-kDa
HDC, and 2) high activity cleaved 53-kDa HDC. Both HDC isoforms are found in
the  endoplasmic  reticulum  of  mammalian  cells,  but  only  the  53-kDa  isoform
undergoes internalization by vesicular monoamine transporter-2 (VMAT-2) to
facilitate storage of the newly produced histamine (Stegaev et al., 2013).
Histamine-producing cells vary considerably in origin and functions. In this
context, our group has coined a new term to differentiate cells based on their
histamine-production characteristics, as either “professional” or “non-professional”
histamine-producing cells (Konttinen et al., 2013). “Professional” histamine-
producing cells (e.g. MCs, basophils and enterochromaffin-like cells) use the low-
molecular weight, post-translationally cleaved, 53-kDa HDC to produce extensive
amounts  of  histamine,  store  it  in  special  granules  and  response  to  stimulants  (eg.
Allergens) by releasing histamine in “burst-release” exocytosis manner. On the other
hand, “non-professional” histamine-producing cells (e.g. epithelial cells and
lymphocytes) utilize the high-molecular weight, full-length, 74-kDa HDC which
produces as low histamine amounts as 100-1000-fold lower rate than MCs.
Moreover, “non-professional” histamine-producing cells do not store histamine in
granules but it is passively transferred along its concentration gradient via histamine
channels such as organic cation transporters or OCTs (Konttinen et al., 2013; Panula
et al., 2015).
Histamine degradation is controlled by two enzymes: histamine N-methyl
transferase (HNMT) and diamine oxidase (DAO), which facilitate ring methylation
and oxidative deamination, respectively (Smolinska et al., 2014). HNMT is a
cytosolic enzyme, and thus it degrades histamine only intracellularly, whereas DAO
is mainly responsible for scavenging histamine from extracellular spaces (Klocker et
al., 2005). Experimental studies showed that HNMT deficiency enhanced brain
histamine concentrations and regulated sleep-wake cycle (Naganuma et al., 2017).
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5.16. Histamine receptors
Histamine-mediated effects occur via four known G-coupled protein receptors
(GPCR) of histamine (histamine H1 through H4 receptor). Firstly, it was noted that
some effects produced by antihistamine compounds were compatible with
antagonizing effects at a receptor that is now called the histamine H1 receptor (H1R;
Panula et al., 2015). The H1R was the first discovered receptor subtype of histamine,
and it was the first to be harnessed as treatment for allergic inflammation (Massari
et al., 2018; Panula et al., 2015).  The first generation of antihistamines paved the
way for very successful medications, which many are still in use. However, some
histamine-mediated effects were not blocked by such H1- antihistamines and a
second receptor was suggested to exist. This has led to the pharmacological
characterization of H2R, the second histamine receptor subtype to be discovered,
which was intended clinically to block the histamine-mediated secretion of gastric
acid (Panula et al., 2015). Later, scientists characterized the third receptor of
histamine, H3R, which showed very promising clinical effects and has been involved
in  studies  targeting  CNS  disorders  (Massari  et  al.,  2018).  Finally,  the  H4R  was
discovered at the turn of the millennium, and it represents the latest characterized
receptor subtype of histamine family (Nakamura et al., 2000; Oda et al., 2000;
Simons and Simons, 2011; Ferre et al., 2014; Panula et al., 2015).
Histamine receptors consist of three main parts or domains: intracellular,
transmembranous, and extracellular domains. The ligand-binding sites of the
receptor are located on the extracellular domain, while different G-proteins are
bound to the intracellular domain Therefore, G-proteins play crucial role in the signal
conduction through histamine receptors via downstream activation/inhibition of
signalling cascades. Activation of histamine receptors will eventually result in
various subsequent events including swift release of calcium ions, protein
phosphorylation, and gene transcription (Konttinen et al., 2013; Tiligada and Ennis
2018).
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In fact, different concentrations of histamine are required to stimulate the
receptor  subtypes.  For  instance,  H1R  and  H2R  have  relatively  low  affinity  for
histamine, and thus require higher histamine concentrations for activation, compared
with H3R and H4R. Therefore, histamine responses are largely based on its local
concentration and what kind of receptor subtype exists in certain tissue. The
increased pace in histamine research area has improved our understanding of
histamine receptor signalling, which was associated with developments in histamine
receptor pharmacology (Ferre et al., 2014; Panula et al., 2015; Tiligada and Ennis
2018). Summary of some features of histamine receptor subtypes are listed in Table
2.
In spite of the fact that histamine has been exploited in medicine for over 80
years, H1R and H2R ligands remain largely ineffective in the management of several
immune-associated diseases particularly those with elevated MC and histamine
levels, such as autoimmune diseases and cancer (Konttinen et al., 2013; Massari et
al., 2018; Panula et al., 2015). This has been attributed to the variation of histamine
levels in various body tissues, as it could be very low to activate the classical low
affinity H1R (pKi = 4.2) and H2R (pKi = 4.3), but high enough to stimulate the high-
affinity H4R (pKi = 8.3) that is expressed on immune cells and tumour tissues
(Thurmond et al., 2008; Konttinen et al., 2013; Massari et al., 2018). Therefore, the
latter novel receptor has generated enormous interests due to the fact that histamine
can exert immunomodulatory effects on different cell types via H4R signalling and
hence it may provide a promising therapeutic target in various diseases (Thurmond
et al., 2008; Konttinen et al., 2013).
5.17. Histamine H4 Receptor
The first evidence of H4R existence was shown when nanomolar
concentrations of histamine increased cytosolic Ca2+ in eosinophils about 7.5-fold
more compared with specific H3R agonists (Raible et al. 1994). The discovery of
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H3R gene has encouraged enthusiasm to search for additional related sequences,
which resulted in a receptor that carries 35% homology to H3R and exhibits a high
affinity for histamine (Table 2).
Table 2. Summary of certain key features of histamine receptor subtypes.
Features H1R H2R H3R H4R
Receptor
cloning
1993 1991 1999 2000
Histamine
affinity (pKi)
4.2 4.3 7.8 8.3

















































































Several groups have later cloned the H4R protein, which has revived the
scientific interest in histamine research as a hot topic for potential therapeutic drug
approaches (Nakamura et al. 2000; Oda et al. 2000; Konttinen et al., 2013).
Interestingly, H4R has been characterized in hematopoietic cells such as eosinophils,
neutrophils, basophils, MCs, NK-cells, dendritic cells and T-lymphocytes (Damaj et
al. 2007), suggesting its crucial role in inflammation and immune responses.
Moreover, H4R activation resulted in increased secretion of IL-16 (from T-
lymphocytes), neutrophils recruitment, chemotactic activity in MCs and eosinophils,
and decreased monocytes secretion of CCL2 chemokine (Gantner et al. 2002;
Takeshita et al. 2003; Buckland et al. 2003; Hofstra et al. 2003; Ling et al. 2004;
Dijkstra et al. 2007).
H4R has also been characterized in non-immune cells, such as the neuronal
cells of nasal mucosa and the grey matter of the spine (Nakaya et al. 2004; Kajihara
et al. 2010; Lethbridge and Chazot 2010). Additionally, H4R receptors were found
to be expressed in the human cortex, and mouse thalamus (Breunig et al. 2007) and
other  regions  of  CNS  tissues  of  both  mice  and  humans  (Connelly  et  al.  2009;
Strakhova et al. 2009). Other cell types that were reported to express H4R include
dermal fibroblasts, dermal keratinocytes, osteoclasts, synovial cells and
chondrocytes (Biosse-Duplan et al. 2009; Yamaura et al. 2013). In fact, such
expression of H4R in a wide variety of tissues and cells suggests a crucial biological
role of this receptor.
5.18. Histamine and H4R in cancer
The role of histamine and histamine receptors in regulating cell growth and
proliferation has been widely studied, and its association with carcinogenesis
remains an attractive area in cancer research (Cianchi et al., 2008; Median and
Rivera, 2010; Massari et al., 2018). Indeed, histamine can regulate various biological
processes associated with tumour growth with different responses based on its local
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concentration and the type of receptor subtype. Such processes including cell
proliferation, migration, differentiation and apoptosis (Faustino-Rocha et al., 2017).
Moreover, MC-derived histamine can affect angiogenesis and the expression of
vascular endothelial growth factor (VEGF), and thus it can regulate tumour growth,
invasion and distant metastasis (Johnson et al., 2016).
Experimental research reports indicate that histamine, through its receptor
subtypes, imparts a regulatory function on mammary cell growth (Median and
Rivera, 2010). Recent in vivo studies demonstrated that xenograft tumours of the
highly invasive human breast cancer cell line MDA-MB-231 were significantly
decreased in growth when stimulated with H4R agonists. Furthermore,
administration of histamine has significantly increased median survival in mice and
tumoural apoptosis (Martinel Lamas et al., 2013). On the other hand, the proliferation
rate of MDA-MB-231 cell line was increased moderately through the H3R pathway;
which signifies the role of histamine concentration and receptor subtype in
determining the outcome (Medina et al., 2006; Medina et al., 2008). However, no
effect on proliferation is observed in the non-tumorigenic HBL-100 cells (Medina
et al., 2006; Medina et al., 2008).
In melanoma, histamine was shown to induce melanogenesis via H2R and
growth-differentiation factor-15 in melanoma cell lines (Lee et al., 2012). In contrast,
the in vitro activation  of  H4R  showed  inhibitory  effects  on  melanoma  cell
proliferation, while the in vivo administration of H4R agonist (JNJ28610244)
exhibited a significant antitumorigenic effect and reduced metastatic potential in
experimental mice (Massari et al., 2017). Furthermore, H3R and H4R are involved
in pancreatic carcinoma cell growth. Targeting H3R in human pancreatic cancer cells
induced their proliferative capacity, whereas such effect was reversed via H4R
agonists (Cricco et al. 2008).
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Meng et al. found that Clobenpropit, a potent H3R antagonist/H4R agonist,
is able to reduce cholangiocarcinoma (CCA) growth and metastases in vivo.
Downregulation of H3R expression or overexpression of H4R significantly
decreased CCA proliferation (Meng et al., 2011). Recent reports indicated that
histamine and H4R are involved in esophageal carcinogenesis (He et al., 2018).
Importantly, H4R exhibited antitumorigenic properties where stimulation of the
receptor significantly blocked cancer cell proliferation and inhibited invasive
properties. Moreover, xenograft-bearing mice treated with H4R agonists were
associated with an increased survival period (He et al., 2018).
5.19. Constitutive or basal H4R activity
A two-state model of receptor activation that describes ligand-receptor interactions
for H4R and other G-protein coupled receptors has been widely accepted (Leff
1995). It is suggested that H4R exists in two states: resting or ground receptor state
(R, GDP-bound), which indicates the absence of a ligand; and active receptor state
(R*, GTP-bound) that characterizes the binding of a ligand to its receptor (signalling
state).
Some G-protein coupled receptors spontaneously attain R* conformation, or
state, and promote G-protein signalling even in ligand absence, which is known as
constitutive or basal activity. H4R exhibits high constitutive activity, compared to
H1R and H2R, which indicates sustained and extended histamine interactions under
physiological and inflammatory conditions (Konttinen et al. 2013). The constitutive
or intrinsic H4R activity is described as the ratio between R* and R, and this intrinsic
activity is considered to be about 50% of H4R total activity (i.e. half-maximally
active), which makes H4R responsive to very low, nanomolar, histamine
concentrations (Thurmond et al. 2008; Jablonowski et al. 2003; Akdis and Simons,
2002).
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Histamine produced by “non-professional” histamine-producing cells is too
low to stimulate the conventional low-affinity H1R and H2R, but sufficiently high
to stimulate H4R. In this regard, the low-affinity H1R and H2R become maximally
activated during allergy and helminthic infections, leading to acute and transient
responses in the host tissue. In contrast, the high-affinity H4R, is believed to maintain
and regulate mechanisms responsible for homeostasis and immunity, and thus it is
also expressed in non-professional histamine-producing cells including various cells
such as dendritic cells, T-cells, and monocytes/macrophages (Kubo and Nakano
1999; Szeberenyi et al. 2001; Konttinen et al. 2013). Additionally, non-immune cells,
such as epithelial cells, mammary gland cell lines, skeletal muscle cells, and sperm
cells produce considerably lower concentrations of histamine (Tanaka and Ichikawa
2011; Niijima-Yaoita et al. 2012).
Another important aspect of such constitutive activity is that receptor ligands
can act as agonists, neutral antagonists or inverse agonists. When agonists bind the
receptor they promote the active (R*) conformation and induce signal transduction.
On the other hand, binding of a neutral antagonist to a constitutively-active receptor
does  not  promote  either  R or  R* states  alone,  but  it  competes  with  an  agonist  for
receptor binding, and therefore inhibits agonist-mediated effects. Importantly,
binding of inverse agonists (formerly were also called antagonists) promotes the
inactive receptor conformation (R-state), which thus inhibits the constitutive receptor
activity (Konttinen et al., 2013).
Indeed, such new findings added extra layer of complexity to our
understanding of histamine signalling, and revived interest in histamine, and its
novel H4R, as viable therapeutic targets in inflammatory disorders and cancer (Dib
et al., 2014; Thurmond 2015).
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6. AIMS OF THE STUDY
The hypothesis of our study was that “histamine and its latest discovered receptor,
H4R, are involved in the pathogenesis of OLP and may contribute to inflammation-
mediated oral carcinogenesis”. To assess this hypothesis, the following objectives
were set out:
 1) To investigate H4R expression and internalization in human oral epithelial cells,
and to determine its cellular sources in OLP;
2) To assess the capacity of oral epithelial cells to synthesize and release histamine,
and to study the role of bacterial/inflammatory mediators in regulating such
processes;
3) To assess the potential outcomes of derangement of histamine metabolism in oral
epithelial cells and its possible contribution to oral mucosal integrity and subsequent
bacterial invasion;
4) To elucidate the role of pattern-recognition receptors (PRRs) in promoting H4R
response by mapping the toll-like receptors in OLP lesions;
5) To investigate the expression of H4R in cancer cell lines and in OTSCC patients.
Additionally, we aimed to study the effects of bacterial components and MC
mediators on oncogene expression in oral epithelial cells;
6) To assess the ability of H4R agonist to modulate the proliferation/apoptosis of
oral epithelial cells;
7) To assess the ability of H4R agonist and inverse agonist to modulate epithelial-
mediated antimicrobial response, and to further envision a potential pro-cancerous,
vicious inflammatory circle in OLP lesions.
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7. MATERIALS AND METHODS
7.1. Ethical Permissions
Studies  utilized  OLP  patient  samples  (I-IV,  VI)  were  approved  by  the  Hospital
District of Helsinki and Uusimaa (Ethical permission number 42/13/03/01/2013).
The  usage  of  OED  (study  IV)  and  OTSCC  (studies  IV,  VI)  patient  samples  was
approved by the Ethical Committee of the Northern Ostrobothnia Hospital District,
Finland (49/2010, 56/2010) and the Finnish National Supervisory Authority for
Welfare and Health (6865/05.01.00.06/2010). Patient involvement in this study was
voluntary; written and signed informed consent was obtained from all participants
(patients and controls).
7.2. Patient Samples
In study I, paraffin-embedded oral mucosal biopsies taken from eighteen OLP
patients and ten healthy controls were included. In study II,  twenty-five OLP and
seventeen  healthy  control  samples  were  used.  In  study III, twenty-five OLP and
fifteen healthy control samples were used. In study IV, seventeen OED (dysplasia
moderata) patients, thirty OTSCC patients and 17 healthy controls.
Histopathologically, OTSCC specimens were graded according to a three-tier
grading scheme (Thompson 2006) as follows: a) grade I, or low-grade tumour, where
the majority of cells are well-differentiated; b) grade II, or intermediate-grade,
tumour where tissues are dominated by moderately-differentiated cells; c) grade III,
or high-grade tumour, which is characterized by poorly-differentiated cancer cells.
In study V,  no  patient  samples  were  used.  In  study VI, we used samples from
fourteen OLP patients, forty OTSCC patients, and fourteen healthy controls.
OLP patients were clinically and histologically diagnosed by specialized oral
pathologists. The inclusion criteria of patients enrolled in this study were as follows:
(a) clinical and histological diagnosis of OLP lesions according to the WHO
recommendation and its 2009 modi cation (Kramer et al., 1978; Rad et al., 2009);
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(b) patients are not diagnosed with any systemic diseases at the time of sampling; (c)
patients have not yet received treatment for OLP or have been o  corticosteroids for
at least twelve months at the time of biopsy; and (d) lesions do not represent any non-
characteristic features of OLP (Rad et al., 2009). OLP samples were obtained from
the department of pathology at Helsinki University hospital. OTSCC samples were
obtained from Oulu University hospital. The OLP biopsies were taken from active
lesion areas, mostly from buccal mucosa. Control samples were obtained from
healthy oral mucosa from volunteers during wisdom tooth extraction. The surgical
procedures were performed under local anaesthesia (xylocaine-adrenaline, 20 mg/ml
12.5 g/ml) by specialised oral surgeons. Samples were preserved in 10% formalin
and then embedded in paraffin blocks. Formalin-fixed, paraffin embedded (FFPE)
samples are stored at room temperature (RT) until further use.
7.3. Cell Culture and Stimulation (studies I, II, IV-VI)
Normal human oral keratinocytes (HOKs)
Primary HOKs and oral keratinocyte culture medium (OKM) were purchased from
Science Cell Research Laboratory (ScienCell, Uppsala, Sweden). Oral keratinocyte
growth supplements and penicillin/streptomycin solution were added to OKM at
concentration of 500 unit per ml. Cells were cultured in a 75 T-flask until 80-90%
confluent was reached. Culturing procedure was performed as described in the
manufacturer’s instruction sheet. For stimulation assays, cells were collected by
adding trypsin-ethylenediaminetetraacetic (EDTA) acid, and cells were then cultured
in a multi-well plates (BD Falcon, Lawrence, KS, USA) and exposed to various
stimulants (Table 3). HOKs were used within cell passages 2-7.
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Table 3. Details of different cell-culture stimulants used in this study.
Protein Company/Provider Concentration Time
Study I
HST-10 Prof. Holger Stark1 50 nM 10, 20, 30,
60 min
Histamine Sigma-Aldrich, MO, USA 50 μM 24 hours
TNF- R&D Systems, MN, USA 10 ng/ml 24 hours
IFN- R&D Systems, MN, USA 10 ng/ml 24 hours
Study II
HST-10 Prof. Holger Stark1 100 nM







Sigma, Steinheim, DE 10 mg/ml 1 hour
TNF- R&D Systems, MN, USA 100 ng/ml 36 hours
NF- B inhibitor
IMD-0354
R&D Systems, MN, USA 125 nM 36 hours
Staurosporine Merk KGaA, DE 100 nM 36 hours
Study III




Histamine Sigma-Aldrich, MO, USA 50 μM 24 hours
TNF- R&D Systems, MN, USA 100 ng/ml 24 hours
IFN- R&D Systems, MN, USA 100 ng/ml 24 hours
Study V
MC-releasate2 Katariina Maaninka3 90 μg/ml 24 hours
IL-17A R&D Systems, MN, USA 100 ng/ml 24 hours
Histamine Sigma-Aldrich, MO, USA 50 μM 24 hours
LPS-binding
protein
R&D Systems, MN, USA 100 ng/ml 24 hours




R&D Systems, MN, USA 50 ng/ml 8 hours
Ultrapure LPS Invivogen, CA, USA 5 μg/ml 24 hours
TNF- R&D Systems, MN, USA 100 ng/ml 8 hours
IFN- R&D Systems, MN, USA 100 ng/ml 8 hours
Histamine Sigma-Aldrich, MO, USA 100 μM 8 hours
HST-10 Prof. Holger Stark1 1 μM 8 hours
ST-1007 Prof. Holger Stark1 1 μM 8 hours
1Institut für Pharmazeutische und Medizinische Chemie, Heinrich-Heine-Universität
Düsseldorf, Germany; 2MC-releasate was prepared as described in this report (Lappalainen
et al., 2007); 3Wihuri Research Institute, Biomedicum Helsinki, Finland.
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Human OTSCC cell lines
Two OTSCC cell lines were used in this research project: the highly-aggressive
OTSCC  cell  line  (HSC-3;  JCRB  Cell  Bank;  Osaka  National  Institute  of  Health
Sciences, Osaka, Japan), in addition to the less-aggressive OTSCC cell line (SCC-
25; ATCC® CRL-1628™, Rockville MD, USA). Both OTSCC cell lines were
cultured in Dulbecco's Modified Eagle Medium (DMEM)-12 (Gibco, Payisley, UK),
10% foetal bovine serum, 1000 U/ml penicillin, 0.1 mg/ml streptomycin, and 0.1%
hydrocortisone (Life Technologies, Grand Island, NY, USA). Confluent cells were
detached, counted and plated in cell culture well-plates for further stimulations
(Table 3).
7.4. Purification of Total RNA (studies I, II, IV-VI)
The total RNA samples from healthy and patient FFPE specimens were purified
using Maxwell® 16 Low Elution Volume RNA-FFPE Kit and AS2000 Maxwell® 16
Instrument (firmware 4.97; Promega Corp, Madison, WI, USA) according to the
recommended isolation program. Total cellular RNA from cultured HOKs and
OTSCC cell lines were purified using RNeasy Mini-Kit (Qiagen, Düsseldorf,
Germany) according to the manufacturer’s instructions. The total amount of RNA
was measured using the NanoDrop 1000 spectrophotometer (Thermo scientific,
Waltham, MA, USA).
7.5. Quantitative Real-Time Polymerase Chain Reaction (qPCR; studies I-VI)
Following total RNA isolation, qRT-PCR was carried out using two μl of first-strand
cDNA and 250 nmol/L primers in iQ SYBR® Green supermix, or in SsoAdvanced
Universal SYBR® Green Supermix (BioRad Laboratories Inc., Hercules, CA, USA),
which is based on Ss7d Fusion Enzyme Technology. Human primer sequences are
listed in Table 4.
7.6. Droplet Digital Polymerase Chain Reaction (ddPCR; study VI)
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The ddPCR is a highly-sensitive technology that can detect a few positive molecules
and rare target mutations (van Ginkel et al., 2017). The ddPCR was performed using
20 l reaction mix that contained 10 l of QX200™ EvaGreen® ddPCR™ Supermix
(Bio-Rad Laboratories), 2 l of cDNA, 1 l of gen primers. Samples were pipetted
into droplet-generator cartridge, then 70 microliters of Droplet-Generation Oil for
EvaGreen was pipetted into the cartridge, followed by droplet generation (QX200™
Droplet-Generator). Forty l of droplets were then loaded into the columns of a 96-
well  PCR  plate,  which  was  sealed  with  a  supplied  foil  in  PX1-PCR  Plate  Sealer
instrument (Bio-Rad). The plate was then loaded into a T100 Thermal Cycler (Bio-
Rad). The sealed plate was then transferred into the droplet reader for detection of
completed PCR reactions in droplets. The data were analysed using and QX200™
Droplet Digital™ PCR Systems (Bio-Rad Laboratories) according to the
manufacturer’s instructions. The Quanta-Soft version 1.7.4.0917 software (Bio-Rad
Laboratories) was used for data analysis.
Table 4. Details of human primer sequences used in this study.
Primer Primer sequences Study






BAX Forward: 5 -CGGGTTGTCGCCCTTTTCTA-3
Reverse: 5 -GTCCAATGTCCAGCCCATGA-3
II, V
HDC Forward: 5 -TTGATTGCCCTGCTGGCAGC-3
Reverse: 5 -TGCACAGACAAAGACGGGCACC-3
III, V
OCT3 Forward: 5 -CGGGTTGTCGCCCTTTTCTA-3
Reverse: 5 -GTCCAATGTCCAGCCCATGA-3
III
HNMT Forward: 5 -TGGCATCTTCCATGAGGAGCTT-3
Reverse: 5 -AAAATCCCAAAGCAGGTCTCCAT-3
III
AOC1 Forward: 5 -GCTACGTCCACGCCACCTTCTA-3
Reverse: 5 -CCCAGGCCACCAGGTCCTCA-3
III
ITGA6 Forward: 5 -GGAGACCCCGGGAGCCTCTTC-3
Reverse: 5 -AGCCCTCCCGTTCTGTTGGCT-3
III
ITGB4 Forward: 5 -CTACACGGTGAAGGCGCGCAA-3
Reverse: 5 -CCAGCAGGGGCTCGAACTTCC-3
III
TLR1 Forward: 5 -CGGAGGCAATGCTGCTGTTCAG-3
Reverse: 5 -TGTAGGGGTGCCCAATATGCCT-3
IV




TLR3 Forward: 5 -TGCCGTCTATTTGCCACACACTTC-3
Reverse: 5 -GTGCACTTGGTGGTGGAGGATGC-3
IV
TLR4 Forward: 5 -CCTGCGTGGAGGTGGTTCCTA-3
Reverse: 5 -CCAGAAAAGGCTCCCAGGGCTA-3
IV
TLR5 Forward: 5 -TGTTGGCGCTGTCCGAACCT-3
Reverse: 5 -AGGTGGTCTCCCATGATCCTCG-3
IV
TLR6 Forward: 5 -AAGAGATCTTGAATTTGGACTCATATC-3
Reverse: 5 -TGAAGCTCAGCGATGTAGTTC-3
IV
TLR7 Forward: 5 -TCTTGGCACCTCTCATGCTCTGC-3
Reverse: 5 -GTGAGGTTCGTGGTGTTCGTGGG-3
IV
TLR8 Forward: 5 -CTGCGCTGCTGCAAGTTACGGA-3
Reverse: 5 -TTGCCCACCGTTTGGGGAACTTC-3
IV
TLR9 Forward: 5 -CCCAGCATGGGTTTCTGC-3
Reverse: 5 -ACTTCAGGAACAGCCAGTTG-3
IV
TLR10 Forward: 5 -CTCCCAACTTTGTCCAGAAT-3
Reverse: 5 -TGGTGGGAATGCAATAGAAT-3
IV
EGF Forward: 5 -ATGCGGTTGTTCCTCACCCG-3
Reverse: 5 -GCTGGCTGAGCAGAGTTCCA-3
V
EGFR Forward: 5 -CTCTTCGGGGAGCAGCGAT-3
Reverse: 5 -AAAGTGCCCAACTGCGTGAG-3
V
hBD-2 Forward: 5 -ATCAGCCATGAGGGTCTTGT-3
Reverse: 5 -GAGACCACAGGTGCCAATTT-3
VI
TNF- Forward: 5 -CTTTGGAGTGATCGGCCCC-3
Reverse: 5 -GGTTATCTCTCAGCTCCACGC-3
VI
NF- B Forward: 5 -CCAGACCAACAACAACCCCT-3
Reverse: 5 -TCACTCGGCAGATCTTGAGC-3
VI
STAT1 Forward: 5 -AGTCTGGCGGCTGAATTTCG-3
Reverse: 5 -GATCACCACAACGGGCAGAG-3
VI
GAPDH Forward: 5 -AAGGTCATCCCTGAGCTG-3
Reverse: 5 -TGCTGTAGCCAAATTCGTTG-3
I-VI
RPLP0 Forward: 5 -GGCGACCTGGAAGTCCAACT-3
Reverse: 5 -CCATCAGCACCACAGCCTTC-3
I-VI
7.5. Immunostaining (studies I-VI)
Immunohistochemistry (IHC)
Formalin fixed and paraffin embedded tissue samples were cut to 5- m sections and
incubated overnight at 37°C. The slides were first deparaffinised, and the antigen
retrieval was performed in 10 mM sodium citrate buffer, pH 6.0, in Micromed T/T
Mega Microwave processing Lab station for Histology (HACKER Instruments &
Industries Inc., Winnsboro, SC, USA) for 25 min at +95°C, followed by cooling at
RT for 20 min. Endogenous peroxide was blocked using 3% H2O2 in phosphate-
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buffered saline (PBS) for 10 min, then washed 3x5 min in PBS. The nonspecific
staining was blocked by incubation in 10% normal serum for 1 hour at RT. Slides
were then incubated with the primary antibodies (Table 5) overnight at +4°C and
washed 3x5 min in PBS. Appropriate biotin-conjugated secondary antibodies against
IgG (Vector Laboratories; 1:200 in 1.25% bovine serum albumin (BSA)-PBS) were
added to the slides for 1 hour and then washed 3x5 min in PBS. Slides were then
followed by incubation with ABC complex (1:200 in H2O, Vector Laboratories) for
1 hour at RT and washed 3x5 min in PBS.  To develop the colour, slides were then
incubated in 0.006% H2O2 and 3,3´-diaminobenzidine (DAB) chromogen for 10 min
at RT and washed 3x5 min in dH2O. Cell nuclei were stained with hematoxylin,
dehydrated and mounted in Mountex (HistoLab, Gothenburg, Sweden). For negative
controls, slides were incubated with non-immune IgG at the same concentration, the
same incubation time, and in the same environment as the primary antibodies.
Antibody concentration was optimized through pilot experiments with controls.
Immunofluorescence (IF)
Cultured cells on coverslips and paraffin-embedded tissue sections were first
permeabilized with 0.5% Triton X-100 for 10 min at RT, and washed 3x5 min in
PBS. Non-specific staining was blocked by incubation in a 10% normal serum for 1
hour at RT. The coverslips and slides were incubated with primary antibodies (Table
5) overnight at +4°C and washed 3x5 min in PBS. Then, they were incubated with
fluorescein-conjugated secondary antibodies for 1 hour at RT, and washed 3x5 min
in PBS. Cells nuclei were stained using 4'6-Diamidino-2-phenylindole (DAPI) for
10 min at RT and washed 3x5 min in PBS. Samples were mounted in Vectashield®
(Vector Laboratories, Burlingame, CA) and kept at +4°C in a dark place for
overnight incubation to ensure an optimum curing time of the reagent. For the
negative staining of controls, slides were incubated with a non-immune IgG at the
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same concentration, duration, and in the same environment as the primary antigen-
specific antibodies. Positive tissue controls were also used where applicable.
Table 5. Primary antibodies used in this study.
Antibody Source and
clonality




H4R Rabbit, p MBL International, MA, USA 1 μg/ml IHC-IF
Tryptase Mouse, m AbD Serotec, Oxford, UK 0.05 μg/ml IHC
Study II
H4R Rabbit, p MBL International, MA, USA 1 μg/ml IHC-IF
cPARP Rabbit, m Abcam, Cambridge, UK 50 mM WB
ERK1/2 Mouse, m Millipore, Temecula, CA 0.25 μg/ml WB
pERK1/2 Mouse, m Millipore, Temecula, CA 0.1 μg/ml WB
pJNK Rabbit, p Millipore, Temecula, CA 1 μg/ml WB
Bcl-XL Rabbit, p Abcam, Cambridge, UK 0.128 μg/ml WB
BAX Rabbit, m Abcam, Cambridge, UK 0.114 μg/ml WB
Study III
HDC Mouse, m Dr. Francisca Sanchez Jimenez1 1:350 IHC
DAO Mouse, m Dr. Hubert Schwelberger2 1:400 IHC
HNMT Rabbit, p Abcam, Cambridge, UK 2.5 μg/ml IHC
OCT1, 2 Rabbit, p Dr. Anne T. Nies3 1:100 IF








H4R Rabbit, p LifeSpan Biosciences, WA, USA 1 μg/ml IHC-IF
MC-
tryptase








Rabbit, p LifeSpan Biosciences,WA, USA 1 μg/ml IHC
CD4 Mouse, m Dako, Glostrup, Denmark 3 μg/ml IF
CD8 Mouse, m Dako, Glostrup, Denmark 1.5 μg/ml IF
CD163 Mouse, m Leica Biosystems, Newcastle, UK 10 μg/ml IF
MC-
chymase
Mouse, m Thermo Fisher Scientific, MA,
USA
5 μg/ml IF
1University of Málaga, Málaga, Spain; 2Medical University Innsbruck, Innsbruck, Austria;
3Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany;
*respectively. m= monoclonal; p= polyclonal.
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7.6. High Performance Liquid Chromatography (HPLC; studies II, V)
HPLC combined with fluorescence detection was used to detect histamine level in
supernatants from bacterial lipopolysaccharides-stimulated and non-stimulated
HOKs.  The  HPLC  system  comprised  of  4  pumps,  autosampler  (SIL-20AC),
fluorescence detector (RF-10Axl) and controller. The software (LC-Solution 1.21)
was employed for system control and data collection and processing. The lower limit
of detection of histamine with signal-to-noise ratio 3:1 was approximately 5 fmol.
We used Yamatodani’s method used for histamine analysis (Yamatodani et al.,
1985).
7.7. Western Blotting (WB; study V)
Following induction of apoptosis, NS-SV-AC cells were collected at different time
points  for  analysis  of  cleaved  poly-ADP-ribose  polymerase  (PARP),  Bcl-XL  and
Bcl-2-associated X (BAX) proteins. After brief centrifugation, cells were lysed and
sonicated the centrifuged again at 14.000 g for 10 min at +4°C. Supernatants were
collected and total protein concentration was measured using Pierce BCA Protein
Assay Kit (Thermo Scientific, IL). Total protein amount of the samples was between
9-22 g per lane. The sample proteins were denatured by heating up at +95°C for 10
minutes, then followed by electrophoresis and blotting samples to methanol-
activated polyvinylidene fluoride (PVDF) membranes. PVDF membranes were then
washed in TBS buffer, blocked in BSA buffer for 1 hour at RT, and incubated
overnight at +4°C in primary antibodies (Table 5).  PVDF  membranes  were  then
washed 3x10 minutes and secondary antibodies were applied for 1 hour at RT. The
membranes were washed 4x10 minutes in TTBS and detection was performed by
chemiluminescent reaction using Bio-Rad Immun-StarTM WesternCTM Kit and Bio-
Rad ChemiDocTM MP Imaging system. Band intensity was analysed by Bio-Rad
Image Lab software.
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7.8. Microscopy and Image Analysis (studies I-VI)
ZEISS Primo Vert microscope (Carl Zeiss Microscopy, Thornwood, NY, USA) was
used to monitor culture and examine cell appearance and growth. Fully-automated
Leica DM6000 microscope equipped with Leica DFC365-FX digital camera (Leica
Microsystems, Wetzlar, Germany) was used to image immunostained sections and
cells. For immunolocalization (study III), cells were photographed using Zeiss
Confocal Laser Scanning microscope (CLSM 880; Zeiss Corp, Oberkochen,
Germany). The staining intensity was measured using ImageJ program (version 1.47;
National Institute of Mental Health, Bethesda, MD, USA). For staining intensity
analysis, three di erent areas per tissue section of OLP samples and controls were
analysed at a eld magni cation of 40x. A stop lter type was used with a hue value
of between 0 and 161. The relative staining intensity of each antigen was determined
by applying the inverse mean grey value.
7.9. Statistical Analysis
Study results are presented as means ± standard deviation, and data were obtained
from at least three independent experiments. Data analysis were performed using
SPSS software programme version 21.0 (studies I-V; IBM SPSS Statistics, SPSS
Inc., Chicago, IL, USA) or GraphPad Prism version 6 (GraphPad Software, La Jolla,
CA) for study VI. In study I, two-tailed Student’s t-test was used, and linear
regression analysis was used to assess the correlation between H4R staining intensity
and MC count. In studies II-VI, two-tailed Student’s t-test or one-way Analysis of
variance (ANOVA) followed by Bonferroni or Tukey’s multiple comparison post-
hoc tests were used to estimate the statistical significance between two-grouped and
multiple-grouped data, respectively. Mann–Whitney U test, or Kruskal-Wallis
followed by Dunn’s multiple comparisons test were applied where appropriate.
Statistical significance was set at P values 0.05. Significance was indicated as *P
0.05, **P 0.01, ***P  0.001, and ****P 0.0001.
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8. RESULTS
8.1. Characterization of H4R in OPMDs, OTSCC, and oral epithelial cell lines
(studies I, IV)
Healthy oral epithelium expressed high levels of constitutive H4R at both protein
and mRNA levels, which exhibited a uniform pattern of staining in healthy epithelial
controls (Figure 4a). On contrary, H4R protein staining was noticeably reduced in
specimens obtained from OLP, OED, and OTSCC patients.
Figure 4. Expression of H4R in: a) healthy oral epithelium, b) OLP, c) OED, d) grade II
OTSCC, e) grade II OTSCC, f) grade III OTSCC; g) H4R mRNA in HOKs and cancer
cells; h) H4R in HOKs and HSC-3.
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In OLP and OED tissues, H4R immunoreactivity was less intense and not detectable
in basal and suprabasal epithelial layers, while H4R-expressing cells were found in
the middle spinous cell layer and with faint and irregular staining of the granular cell
layer  (Figure  4b,  c). In OTSCC tissues, H4R protein immunopositivity was
decreased in all cases and, interestingly, exhibited a clear grade-dependent manner,
with least detectable H4R-immunoreactivity in grade III samples (Figure 4d-f).
These findings were also supported by low H4R expression in HSC-3 and SCC-25
cells (Figure 4g). Immunocytochemistry results revealed high expression of H4R in
normal HOKs compared with very faint and inconsistent immunostaining in OTSCC
cells (Figure 4h).
8.2. High histamine concentration and IFN-  downregulate H4R expression in
HOKs (study I)
Quantitative RT-PCR results showed that the mRNA expression of H4R was
significantly downregulated in oral epithelial cells after 24 hour exposure to 50 μM
histamine and 10 ng/ml IFN- . The effect of TNF-  was statistically not significant
(Figure 5a).
8.3. Negative correlation between MCs and H4R in OPMDs and OTSCC lesions
(studies I, IV)
MC-tryptase staining revealed few MCs in healthy control samples compared with
higher cell count in OLP and OTSCC tissues. Moreover, we found a clear negative
correlation between degranulated MCs and the staining intensity of H4R in oral
epithelium  of  OLP  lesions  (Figure 5b).We assessed MC distribution in tissue
biopsies  of  OLP,  OED  and  OTSCC.  MCs  were  markedly  increased  in  OLP  and
OTSCC tissues mainly in the lamina propria and subepithelial connective tissue
regions, while a moderate rise in MC count was seen in OED (Figure 5c). Of note,
MC count was highest in grade III OTSCC samples.
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Figure 5. a) MC mediators affect H4R expression; b) MCs correlate negatively with H4R
staining intensity, triangles represent healthy samples, pentagons represent OLP; c) MC
Tryptase staining in different lesions.
8.4. Rapid internalization of H4R in human oral epithelial cell lines (studies I,
V)
Although we showed that human oral epithelial cells express H4Rs, it was necessary
to test if such cells can bind and internalize the specific ligands of H4R. To avoid
potential cross-binding of histamine with the other receptors, cells were stimulated
with  H4R-specific agonist HST-10 [N-(3-(1H-imidazol-4-yl) propyl)-2-
cyclohexylacetamide], which has been suggested as the most selective agonist to
human H4R (Kottke et al., 2011). Cells were stimulated for different times at +37°C
(Table 3). For HOKs and NS-SV-AC cells, non-stimulated, zero time-point controls
showed weak or no labelling signal. However, an increased staining intensity of H4R
was observed at 5, 10 and 20 min time points, which then turned into cytoplasmic
and becomes somewhat weaker at 30 min, until it disappears after 60 min stimulation
with HST-10 (Figure 6a).
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Figure 6. a) Internalization of H4R ligand (HST-10) in cultured HOKs; b) Histamine
metabolizing molecules are deranged in OLP lesions; c) High histamine levels affect
mRNA expression of integrins in HOKs.
8.5. Histamine metabolism capacity is deranged in OLP lesions (study II)
We  showed  in  the  second  study  that  normal  HOKs  are  equipped  with  histamine
metabolizing capacities, including HDC, OCT3 and HNMT molecules. In OLP
lesions, HDC and OCT3 levels were increased while HNMT was decreased
compared  with  healthy  controls  (Figure 6b). OCT1/OCT2 showed weak and
inconsistent staining patterns, whereas DAO was negative in HOKs (not shown).
Next, we investigated the potential consequences of deranged histamine metabolism
in oral mucosa, and whether surplus histamine can affect the integrity of oral
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epithelium. Our data disclosed a significant downregulation of integrin- 6 and
integrin- 4 transcripts in HOKs when exposed to 50 μM histamine for 24 h (Figure
6c). These genes were also downregulated in samples from OLP patients (data not
shown).
8.6. Bacterial lipopolysaccharides (LPS) induces histamine synthesis and
release by normal HOKs (study II)
Next, after having confirmed the presence of histamine metabolizing molecules in
normal cultured HOKs, we studied the potential inflammatory and environmental
mediators that govern histamine metabolism in oral epithelium. Therefore, HOKs
were stimulated by bacterial LPS and MC-derived mediators (INF- , histamine and
TNF- ). After 24 hours of stimulation, HDC mRNA  was  upregulated  with  the
highest expression seen at 5, 1 and 0.05 μg/ml (P = 0.003; 0.01; 0.02 respectively;
Figure 7a). Similarly, stimulation with IFN-  (100 ng/mL) significantly upregulated
HDC, OCT3 and HNMT transcripts in HOKs (P = 0.02; 0.03; 0.03, respectively),
while 50 μM histamine and 100 ng/mL TNF-  showed inhibitory effects (Figure
7b-d).  Furthermore,  when  HOKs  were  exposed  to  LPS,  HPLC  analysis  of  the
supernatants showed that LPS-stimulated cells produced low (picomolar)
concentrations of histamine that were detectable at 36 hours. The highest histamine
level was detected in response to 0.05 μg/mL LPS (2.2 pmol/ml; P = 0.02; Figure
7e).
8.7. Altered expression of TLR family in OLP lesions (study III)
After having confirmed the involvement of bacterial LPS in histamine synthesis and
metabolism in human oral epithelium, we next mapped the main innate sensors of
such invading bacterial components—TLRs.
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The TLR family is a crucial group of PRRs that mediate the recognition of invasive
pathogens (e.g. LPS) by immune cells. Once activated, TLRs induce production of
proinflammatory cytokines that can initiate and perpetuate the inflammatory lesions.
Interestingly, the immunoreactivity for all TLRs was increased in OLP, except for
TLR5, which was noticeably decreased. On gene level, TLR1, TLR2, TLR4, TLR7,
TLR8, and TLR9 transcripts were upregulated in patients compared with controls. On
contrary, TLR3, TLR5, and TLR6 transcripts were negatively regulated in OLRs.
TLR10 remained unchanged in both study groups. Our findings are summarized in
Table 6.
The intensity of TLR staining was scored in the basal/suprabasal, intermediate and
upper cell layers of the oral epithelium. The intensity of TLR immunoreactivity in
Figure 7. a-d) LPS and MC mediators regulate histamine synthesis in human oral
epithelial cells; e) LPS induces histamine synthesis and release from cultured normal
HOKs in dose-dependent manner.
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healthy control and OLP patient samples is  expressed as follows: (-)  to indicate a
negative TLR-staining; (+) weakly positive TLR-staining; (++) moderately positive
TLR-staining;  and  (+++)  for  a  strongly  positive  TLR-staining.  Scoring  was
performed by three independent researchers, who were blinded to the information of
the study samples and antibodies.
Table 6. Intensity of TLR-immunoreactivity in different epithelial layers of OLP
samples.
Basal/suprabasal layers Intermediate layers Superficial layers
Control OLP Control OLP Control OLP
TLR1 +++ +++ + ++ - ++
TLR2 +++ +++ + +++ - +++
TLR3 +++ +++ + +++ + ++
TLR4 +++ +++ + +++ - +++
TLR5 +++ + ++ - + +
TLR6 +++ ++ + ++ - +++
TLR7 +++ +++ + +++ - +++
TLR8 +++ +++ - ++ - ++
TLR9 +++ +++ + +++ - +++
TLR10 + + - + - -
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8.8. MC-derived mediators and LPS regulate oral oncogene expression in HOKs
(study IV)
We performed gene analysis assays to ascertain whether MC-derived mediators or
bacterial LPS can influence the expression of certain genes associated with oral
carcinogenesis. Hence HOKs were stimulated with IL-17, MCR, histamine and LPS
for 24 hours, as detailed in Table  3. Both IL-17A and MCR upregulated the
expression of two oncogenes: EGF (P = 0.002; 0.009, respectively) and EGFR (P =
0.030; 0.010 respectively). In contrast, MCR downregulated Bcl-2 (P  >  0.05)  and
Bcl-xL (P = 0.007) genes, while histamine downregulated Bcl-2 (P = 0.005)
expression. LPS significantly upregulated EGFR expression (P = 0.002). EGF also
tends to be induced by LPS; however, the difference was not statistically significant
(Figure 8a).
8.9. Activation of H4R modulates oral cell proliferation in a dose-dependent
manner (study V)
TNF-  combined with NF- B inhibitor (IMD-0354) induced apoptotic signals in
normal oral (NS-SV-AC) cells. Interestingly, H4R agonist (HST-10) seems to
exhibit a dual effect based on its concentration. Lower “nanomolar” concentrations
of HST-10 inhibited cell apoptosis in a dose-dependent manner. Phase contrast
microscopy disclosed that 100 nM of HST-10 was able to preserve cell structure and
prevented signs of cell apoptosis (Figure 8b). QRT-PCR showed up-regulation of
anti-apoptotic Bcl-XL mRNA and protein in H4R-stimulated samples, however, no
effect was observed on BAX expression (Figure 8c). Furthermore, H4R-agonist
diminished cleavage of the early apoptotic marker PARP (Figure 8d) and flow
cytometry showed significant dose-dependent inhibitory effect of H4R stimulation
on apoptosis (not shown).
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Figure 8. a) MC-derived mediators and LPS regulate the expression of several oncogenes
in HOKs; b) Figures from phase-contrast microscopy shows the effect of H4R-agonist
(HST-10) on NS-SV-AC cell apoptosis; c) up-regulation of anti-apoptotic Bcl-xL mRNA
upon HST-10 stimulation while pro-apoptotic BAX gene remains unchanged; d) HST-10
inhibited the early apoptotic marker PARP in NS-SV-AC cells.
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8.10. Induced expression of hBD-2 in OLP (study VI)
In addition to their role in OLP pathogenesis and histamine signalling, LPS and MCs
are considered the main inducers of epithelial hBD-2, which has also been implicated
in OSCC pathogenesis and progression (Verma et al., 2007; Shi et al., 2014). To
investigate the potential relationship between LPS, histamine and hBD-2 signalling
in oral carcinogenesis, immunohistochemical analysis was performed on patient and
control tissue samples. HBD-2 expression was either negative or very faint in healthy
controls compared with high hBD-2-immunoreactivity in OLP lesions (Figure 9a).
Interestingly, hBD-2 protein was also induced in OTSCC specimens as compared
with controls, but the expression was in general less intense in cancer tissue than in
OLP. This finding was also consistent with ddPCR results obtained from healthy and
OLP samples, which revealed upregulated hBD-2 transcript in OLP patients (Figure
9b). HBD-2 was expressed in normal HOKs, while it  was not detected in OTSCC
cells (Figure 9c).
8.11. LPS and inflammatory mediators stimulate hBD-2 expression in HOKs
(study VI)
Based on the previous findings that histamine, cytokines and LPS are involved in
OLP and OTSCC pathogenesis, we therefore investigated the potential effect of such
mediators on hBD-2 expression in HOKs. As expected, LPS and IFN-  significantly
(P=0.03; 0.02, respectively) induced hBD-2 mRNA  in  cultured  normal  HOKs
compared with the non-stimulated control cells. TNF-  alone slightly induced hBD-
2 mRNA (Figure 9d).
8.12. Subepithelial MCs and macrophages produce hBD-2 in OLP (study VI)
Immunostaining revealed that hBD-2 was expressed in OLP samples in epithelial
cells and lamina propria alike, and hence we investigated the plausible
“subepithelial” sources of hBD-2 in OLP lesions. Double-label immunofluorescence
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staining revealed a very faint hBD-2 in CD4+ and CD8+ T-lymphocytes. CD163+
macrophages were positive for hBD-2. Subepithelial MCs (expressing chymase)
revealed strong expression of hBD-2+ (Figure 9e).
Figure 9. a) Faint staining of hBD-2 in normal oral epithelium which is more confined in
the uppermost superficial layers (arrow). OLP lesions exhibited strong epithelial and
subepithelial hBD-2 expression; b) hBD-2 transcript was highly induced in OLP patients;
c) hBD-2 mRNA was expressed in normal HOKs but not detected in OTSCC cell lines
(HSC-3 and SCC-25; d) LPS and IFN-  induced hBD-2 mRNA in HOKs; e) hBD-2
staining was very weak in subepithelial CD4+ and CD8+ lymphocytes in OLP. CD163+
macrophages were more intense for hBD-2. Subepithelial MCs revealed strong expression
of hBD-2.
64
8.13. Histamine effect on hBD-2 production in HOKs (study VI)
Next we investigated the role of histamine and LPS on hBD-2 production in HOKs.
Histamine alone did not have an effect on the hBD-2 mRNA level, but it enhanced
TNF- -mediated upregulation of hBD-2 mRNA  (Figure 10a). Furthermore,
histamine regulated the transcriptional promoter region of hBD-2. Histamine
mediated the TNF- -induced expression of NF- B p65 and the IFN- -mediated
STAT1 expression (P = 0.006) (Figure 10b-c). This was further confirmed by
immunofluorescence staining, which revealed intense expression of activated NF-
B p65 and p-STAT1 in OLP patients compared with healthy controls (Figure 10d).
8.14. Activation of H4R modulates TNF - and LPS-mediated hBD-2 pathways
(study VI)
After reporting that activation of H4R enhanced prosurvival signals in oral NS-SV-
AC cell lines, which protected cells from apoptosis (study V), we further show that
H4R targeting can regulate hBD-2 expression in HOKs. Cells were initially pre-
treated  with  1  μM  of  HST-10  or  ST-1007  for  8  hours,  and  then  stimulated  with
inflammatory mediators (8 hours; Table 3) or 5 μg/ml LPS (24 hours). Interestingly,
histamine/TNF- -induced hBD-2 expression was upregulated in ST1007-challanged
HOKs (P = 0.04).  In contrast, the same pathway was downregulated in HOKs with
HST-10 (Figure 10e). Similarly, hBD-2 was induced in HOKs stimulated with ST-
1007 and LPS (P = 0.06), while HST-10 diminished such effect in a similarity to the
histamine/TNF- -mediated pathway (Figure 10f).
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Figure 10. a) Histamine (HA) together with TNF- , but not alone, induced hBD-2 mRNA
in HOKs; b and c) Histamine synergistically influenced the promoter region (NF- B p65
and STAT1) of hBD-2 transcript via both TNF- - and IFN- -mediated pathways; d)
Induced expression of activated NF- B p65 and p-STAT1 in OLP samples compared with
healthy controls; e and f) Targeting of H4R modulated hBD-2 expression in HOKs via
both histamine and bacterial LPS.
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9. DISCUSSION
The most recently discovered member of histamine receptor family, H4R, is
essentially expressed by cells of the haematopoietic lineage, immune system, and
also on other cell types including cancer cell lines (Thurmond et al., 2008). Such a
wide distribution of H4R reflects the crucial immunomodulatory role of this novel
receptor, not only in innate and adaptive immune responses, but also in
carcinogenesis (Zampeli and Tiligada 2009; Medina and Rivera 2010; Thangam et
al., 2018). Accordingly, recent reports indicate the involvement of H4R in mediating
the pathogenesis of several disorders, such as autoimmune diseases, bronchial
asthma, pruritus and cancer (Thurmond et al., 2008; Ohsawa and Hirasawa 2012;
Neumann 2017; Sterle et al., 2018). Indeed, these findings signify the therapeutic
potential of H4R ligands, which have already been translated into clinical settings
for the treatment of chronic pruritus and AD (Thurmond et al., 2015).
In fact, human skin keratinocytes were shown to express functional H4Rs,
which have been implied in itch and AD pathology (Gutzmer et al., 2011; Yamaura
et al., 2013). Here we show that healthy human oral mucosal epithelial cells express
H4R protein and mRNA. However, immunostaining assays disclosed a marked
alteration in H4R immunoexpression and diminished staining intensity in OLP, OED
and OTSCC tissues compared with the healthy oral epithelium. The exact reason for
this dramatic loss of H4R-immunoreactivity is not yet understood. However, based
on the mechanistic in vitro experiments, we suggest that such loss may result from
the combination of swift “burst-released” MC-derived histamine (micromolar levels)
and slow cytokine-mediated effects. Such explanation is also supported by our
findings that negative association exists between local MCs and H4R
immunoexpression in the lesional samples, and that MC-releasate downregulated
H4R in HOKs. MCs were markedly increased in OLP and OTSCC tissues mainly in
the lamina propria and connective tissue regions. In fact, MCs play important roles
in cancer-associated events (e.g. angiogenesis and matrix degradation). This has
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been discussed in the literature review (section 5.14).  Of  note,  MCs  can  induce
protumorigenic immunoregulation by inducing immunosuppressive and phenotypic
changes in tumour-associated regulatory T cells (Kalesnikoff and Galli 2011; Ribatti
et al., 2018).
It was also interesting, in the same context, that H4R immunoexpression was
negatively correlated with the respective OTSCC grade. Multiple independent
studies have assessed and recognized the prognostic value of tumour histological
grade, which reflects the degree of cancer cell differentiation (Henson et al., 1991;
Rakha et al., 2008; Rakha et al., 2010). In fact, the histological grade of tumours,
when adequately prepared and stained samples, has been considered as a simple,
affordable and reliable indicator to interpret tumour behaviour and patient prognosis,
as in breast cancer (Rakha et al., 2010). Prognostic evaluation for OTSCC has long
been based on cTNM classification, however, this staging system does not take into
account the biological activity of tumour cells, and thus it must be supplemented by
more precise methods (Akhter et al., 2011). In this regard, and based on our findings,
testing the prognostic value of H4R expression in OTSCC patients could be one
option. This, however, was not possible in the present study due to the lack of the
clinical follow-up data and the limited sample size of OTSCC patients.
The mRNA levels of H4R were also investigated in oral cancer cells, which
further supported the transcriptionally attenuated H4R gene in OTSCC. This is also
in agreement with a previous study, in which H4R mRNA levels were significantly
downregulated in colorectal carcinomas compared with normal enterocytes (Fang et
al., 2011). Additionally, authors suggested that such attenuation of H4R level could
probably happen gradually during the course of carcinogenesis (Fang et al., 2011).
These findings may ultimately unravel the plausible effect of histamine, mediated
via H4R, on tumour development and progression.
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In spite of the abundance expression of H4Rs in human oral epithelial cells,
it was highly important to assess the ability of these cells to bind and internalize the
specific ligands of H4R. Consequently, this has been proven in two distinct cell lines:
the normal HOKs and NS-SV-AC cells. Indeed, the internalization assays revealed
an efficient and fast cellular mechanistic response to low doses of H4R-selective
agonist, which starts as soon as 5 min and is completed one hour after stimulation.
Furthermore, we show that human oral epithelial cells are equipped with functional
molecular machinery necessary for histamine synthesis, transport and degradation.
In  fact,  H4R has  high  affinity  (pKi  =  8.3)  for  histamine  that  is  about  10  000-fold
greater  than  the  classical  H1R  and  H2R  (Walter  and  Stark  2012).  It  is  therefore
interesting that cultured normal HOKs were able to synthesize and continuously
release very low levels of histamine into extracellular supernatants in autocrine and
paracrine manners. We suggest, based on these findings, that human oral epithelial
cells are “non-professional” histamine producing cells (section 5.15). Our finding is
congruent with another study, which showed that histamine was released from
human skin keratinocytes into the extracellular environment after exposure to
ultraviolet light (Malaviya et al., 1996).
Histamine metabolizing molecules exhibit deranged levels in many
inflammatory and malignant disorders, such as AD and breast cancer (Gutowska-
Owsiak et al., 2014; Medina and Rivera 2010). Here we report that histamine
metabolism is also deranged in oral mucosa of OLP patients. Moreover, the high
surplus histamine in lesional oral epithelium, which may accumulate due to HNMT
attenuation or from locally-degranulated MCs, may contribute significantly to the
impaired mucosal integrity in OLP. This is supported by the inhibitory effect of
histamine on the expression of integrin- 6 and integrin- 4, which are involved in
epithelial cell–cell and epithelial cell–extracellular matrix interactions. Importantly,
the loss of such crucial integrins can provoke serious mucosal blistering and
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ulcerations, compatible with the pathognomonic symptoms of some forms of OLP
(Bouvard et al., 2013).
In fact, the impaired epithelial integrity and ulcerative mucosa in OLP lesions
can facilitate bacterial invasion, as well as access of other pathogen- or damage-
associated molecular patterns (PAMPs or DAMPs), into deeper epithelial layers
(Ismail et al., 2007; Salem et al., 2018). Recently, Choi et al. showed that epithelial
layers of OLP lesions were occupied by high levels of intruding bacteria, which were
also detected in the subepithelial lymphocytic cell infiltrate (Choi et al., 2016). Of
note, gram-negative bacterial species (e.g. Porphyromonas gingivalis), with its
hallmark LPS, were highly increased in OLP lesions (Choi et al., 2016; Wang et al.,
2016). Such bacteria have also been implicated in oral carcinogenesis, and viable
bacteria were isolated from OSCC (Sakamoto et al., 1999; Hooper et al., 2006;
Abdulkareem et al., 2018). However, the bacterial role in OLP-mediated
carcinogenesis should be interpreted with caution as the clinical presentation of OLP
patients can be noticeably different from those diagnosed with OTSCC (e.g. gender,
age and intraoral distribution). Our explanation is that such variability could in part
be attributed to certain key factors that may influence the putative carcinogenesis
process including hormones, and male lifestyle habits, such as smoking and alcohol
consumption (Petti 2009). Moreover, lateral border of tongue is considered as one of
the most common sites for OLP occurrence after buccal mucosa and gingiva (Müller
2017; Cheng et al., 2016). Here, we further assert the role of LPS in OLP pathology
by revealing its role in regulating histamine metabolism and stimulating histamine
release from cultured HOKs (study II). Once invaded the superficial epithelial
layers, LPS molecules are recognized by PRRs (e.g. TLRs) that constitutively
expressed in oral epithelial cells.
Recognition of PAMPs/DAMPs is indeed a vital element for the initiation of
proper immune responses and inflammation. Members of TLR-family can mediate
70
such recognition process by initiating innate immune responses and orchestrate the
adaptive arm of host immunity to fight infections (O'Neill et al., 2013). Bacterial cell
wall components are mainly detected by membranous TLRs whereas nucleic acids
are detected by intracellular TLRs (Kawai and Akira 2011). This could explain our
findings that TLR-architecture in OLP patients was, and for most receptors, induced
and shifted towards upper epithelial layers to combat the invading pathogens.
Namely, TLR1, TLR2, TLR4, TLR7, TLR8, and TLR9 were strongly upregulated in
OLL samples at both protein and gene levels. Components of gram-negative as well
as gram-positive bacteria can be detected by many of these TLRs, such as TLR2
(lipoproteins, peptidoglycans, and lipoteichoic acid), TLR4 (LPS), TLR7
(streptococci-derived RNA), TLR9 (DNA motifs) and others (Akira et al., 2006;
Mancuso et al., 2009). These findings, taking together, suggest a fundamental role
of TLR-mediated response to invading pathogens in the initiation and perpetuation
of OLP lesions.
Beside its role in histamine metabolism, LPS has the potential to mediate
OSCC development and progression, and TME is well  suited for bacterial  growth
and survival (Kurago et al., 2008). Importantly, we show that ultra-pure LPS and
MC-derived mediators can significantly induce the expression of certain genes
implicated in oral carcinogenesis. The signalling scheme behind this effect is still
poorly understood. However, it was suggested that LPS can directly induce HOKs
and cancer cells to produce cancer-promoting factors, and activating STAT3/IL-6
pathway (Kurago et al., 2008). Mediators from MCs were also shown to perpetuate
inflammation and induce protumorigenic changes in mucosal tissues and predispose
patients to colon cancer (Gounaris et al., 2007; Gounaris et al., 2009). Nevertheless,
the mechanisms governing precancerous inflammation and oral oncogenesis via
MCs and LPS remain to be further elucidated.
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The persistent apoptosis of basal keratinocytes is a key process in OLP
pathogenesis, which also shapes its potential transformation to OSCC (Zhao et al.,
2018; Tampa et al., 2018). Apoptosis causes loss of oral epithelial cells,
compromises the epithelial protective barrier, and, if not properly cleared,
perpetuates the precancerous inflammatory reaction, and even cancer (Poon et al.,
2014; Zhao et al., 2018; Tampa et al., 2018).  The handling of such abnormal, and
massive, apoptotic bodies likely poses a challenge for system-scavenging apoptotic
bodies (Al-Samadi et al., 2015). Therefore, recent research efforts have focused on
suppressing such refractory apoptotic process in oral epithelial cells (Wu et al., 2017;
Zhao et al., 2018). We explored the role of H4R in oral epithelial cell apoptosis as
well as the protective mechanism of HST-10 signalling against TNF- -mediated cell
death. Interestingly, our findings suggest that H4R attenuates cell apoptosis by
repressing the expression of B-cell lymphoma protein 2 (BCL-2) family.
Indeed, normal oral epithelium provides the first line of defence against
microbial invasion by secreting potent antimicrobial peptides including, inter alia,
hBD-2 (Ganz 2003). This defensive barrier is impaired in many OPMDs, including
OLP (Darido et al., 2016; Choi et al., 2016; Danielsson et al., 2017). In this study,
we report that hBD-2 is highly induced in OLP and OTSCC lesions as compared
with normal oral epithelium. Furthermore, we show that hBD-2 expression was
attenuated in cancer tissues and cells compared with OLP lesions, suggesting an
association between hBD-2 expression and the initiation and progression of OTSCC.
These findings are in agreement with previous studies showing waned levels of hBD-
2 mRNA in samples obtained from OSCC patients (Joly et al., 2009; Abiko et al.,
2001).
Supporting the previously discussed LPS- and MC-driven effects in oral
epithelium, we also demonstrate that hBD-2 in HOKs was induced, and partly
regulated, by LPS and MC-derived mediators. In fact, immunofluorescences staining
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results suggest that MCs are involved in hBD-2-mediated pathogenesis of OLP via
two pathways: 1) as its major “non-epithelial” source, they release hBD-2 upon
activation; 2) they release histamine, which can induce hBD-2 release from oral
epithelium (Kanda and Watanabe, 2007). Importantly, hBD-2 can subsequently
stimulate MCs to release more histamine, which leads to further production of hBD-
2 in a proinflammatory vicious circle (Niyonsaba et al., 2001; Subramanian et al.,
2013).
Histamine has synergistic effect on hBD-2 production via TNF-  and IFN- .
It is probably driven through the upregulation of hBD-2 promoter region, which
contains  two  binding  sites  for  NF- B  and  one  site  for  STAT1  (Mineshiba  et  al.,
2005). Interestingly, activation of H4R regulated hBD-2 mRNA level in HOKs. H4R
agonist seems to downregulate the histamine/TNF- - and LPS-mediated signalling
pathways, while the inverse agonist, ST-1007, potentiated their effect. In this
regards, H4R shows suppressive effect on both STAT1- and TNF- -mediated effects
(Horr et al., 2006), and thus it is logical to assume that such HST10-mediated effect
could  also  be  mediated  by  interfering  with  one  or  both  pathways  (Figure 11).
Supporting this assumption, H4R expression is low in OPMDs and cancer, which
could partly elucidate the dysregulated hBD-2 response in such lesions.
Figure 11. The effect of histamine (HA) on hBD-2 production is likely mediated via
NF- B and, to less extent, via STAT1; hBD-2 promoter region contains two sites for
NF- B and one site for STAT1, which both are induced by HA signalling. Effect of
H4R on hBD-2 in HOKs could be mediated via both STAT1 and NF- B axes.
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10. STUDY CONCLUSIONS AND LIMITATIONS
Based on the presented findings, we conclude that human oral epithelial cells are
“non-professional” histamine producing cells—capable to synthesize, release, and
degrade low levels of endogenic histamine. We also conclude that H4R expression
and histamine metabolism are deranged in OLP patients, where high levels of
histamine could downregulate key integrity molecules in HOKs, and may enhance
subsequent bacterial invasion. In this regard, our findings suggest a potential role of
TLRs in OLP pathogenesis, probably by binding bacterial components (i.e. LPS) and
enhancing further immune response and histamine production. In addition, our
results indicate that histamine/H4R crosstalk signalling with LPS and MCs could
partly be involved in OTSCC pathogenesis. This was further supported by the
deranged H4R expression and the ability of H4R to regulate cell apoptosis and
modulate antibacterial response in HOKs. Therefore, the aims of this study were
fulfilled accordingly.
Putting pieces together, we propose the following overall scenario to envision
the inflammatory cascade in OLP lesions and the potential oral carcinogenesis
(Figure 12): a) the impaired epithelial barrier in susceptible patients facilitates
bacterial invasion into deeper epithelial layers; b) pathogens (e.g. LPS) bind to TLRs
expressed by deeper residing cells and induce antimicrobial response and histamine
synthesis; c) epithelial cell-derived hBD-2 (and histamine?) binds Mas-related gene
X2 receptor (MrgX2) expressed on MCs and induces their degranulation
(Subramanian et al., 2013); d) MC mediators provoke proinflammatory response and
recruit more inflammatory cells; e) elevated levels of surplus histamine and hBD-2
may cause further epithelial degeneration and attenuate epithelial H4R, which seems
to play crucial immunoregulatory functions by modulating characteristic features of
OLP pathology such as epithelial cell apoptosis and antimicrobial response; f)
persistent exposure to LPS and MC mediators perpetuates the vicious inflammatory
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circle by recruiting more immune cells and driving angiogenesis (angiogenic switch)
that could, overtime, promote oral carcinogenesis.
Figure 12. The proposed scenario for the inflammatory cascade in OLP lesions.
Taken together, our findings suggest a possible involvement of H4R in OLP
pathogenesis. Additionally, the attenuated expression of H4R in OTSCC and the
mechanistic in vitro effects of histamine suggest a potential role in oral
carcinogenesis. Recently, development of molecules to target specific steps in the
progression from premalignant lesions to oral cancer has gained enormous attention
(Tanaka and Ishigamori 2011). Therefore, further fictional and preclinical studies of
H4R signalling are warranted to assess whether it serves as a promising molecular
target for therapeutic interventions in OLP and OTSCC. There are several limitations
in this PhD thesis and that should be taken into considerations. We acknowledge that
some clinical and follow-up data of the studied OLP/OED patients were not
available, and therefore assessing the potential tumorigenic transformation in such
lesions was not possible. This also applies to the follow-up data of OTSCC patients
and thus prognostic analysis was not achieved. A relatively small sample size and
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lack of animal model experiments should also be acknowledged. Hence, further
studies to overcome the present limitations and to validate our findings in preclinical
in vivo models are warranted.
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